The Society for Basic Urologic Research (SBUR) was formed in 1986 and is the pre-eminent US-based urologic research society. Our members include molecular and developmental biologists, oncologists, immunologists, epidemiologists, andrologists, biochemists, bioinformaticians, and clinical urologic surgeon-scientists from academia, industry and government. SBUR scientists’ expertise includes the study of urologic cancers (prostate, bladder, kidney, testis, penis), the biology of benign diseases of the prostate, bladder and kidney, developmental biology, kidney and bladder function, autoimmune urologic diseases, infectious diseases, neurourologic diseases, male reproductive biology, infertility and erectile dysfunction.

Our members are based around the globe, including in the United States, Europe and Asia. The active membership of SBUR includes 234 PhDs, 145 MDs, 39 MD/PhDs and 52 other Researchers.

The SBUR 2019 Annual Meeting entitled, “Novel Discoveries in Urology: Big Data to Microbiome” provides a unique environment to learn about the most recent advances in basic, translational and preclinical urologic research, in addition to providing a dynamic forum for discussing how these advances could be implemented for the prevention and treatment of urological diseases.

Much has been learned over the last decade regarding the molecular determinants and key pathways that regulate normal and disease processes, and a wide variety of novel therapeutic and diagnostic strategies have emerged as a result. Thus, this year’s meeting will focus on a few areas that are emerging as the cutting-edge advances in urology, including:

1) Big data (genome, transcriptome, proteome, and metabolome) analysis that is driving the personalized and precision medicine initiative;
2) Endocrine and metabolic dysfunctions that have not been well studied in urologic diseases;
3) Immunology and immunotherapy that urology is lagging behind other fields;
4) Benign urologic disease that is the focus of several NIDDK-funded O’Brien centers and P20 programs;
5) Innovative technologies that have emerged in urologic research; and,
6) Microbiome and inflammation that are pushing forward our knowledge to a new level.

Target Audience
This meeting is intended to meet the needs of molecular and developmental biologists, oncologists, immunologists, epidemiologists, andrologists, biochemists, bioinformaticians, and clinical urologic surgeon-scientists.

Learning Objectives
Following completion of these educational programs, participants will know and be able to:

• Examine recent findings in studying the basic mechanisms of urologic diseases in the areas of transcriptome, genome and epigenome, metabolism, immunology, microbiome, therapeutics, and diagnostic/prognostic markers.
• Identify critical knowledge gaps and stimulate approaches to address them.
• Disseminate and facilitate novel discoveries in urologic diseases.
• Explain the cutting-edge advances in urological cancer therapeutics including mechanisms of resistance and novel approaches in overcoming resistance.
• Describe the outcomes of recent clinical trials on potential new drugs.
• Compare and discuss emerging clinical biomarkers for prostate cancer detection.
• Identify the new tools in analysis of big data generated from omics studies.
• Demonstrate the potential new targets in urological cancers.
• Discuss the novel technologies in urologic research.
• Update cancer immunology and immunotherapy in urological cancer field.
• Assess the role of microbiome and inflammatory microenvironment in malignant urologic diseases.
• Describe leukocytic phenotypes in BPH and how they contribute to disease progression.
• Recognize the importance of basic research in benign urologic disease.
• Recognize how therapeutic intervention targeted to the epigentics might be useful for the treatment of urological cancer.
• List tools essential for the successful training of young investigators for careers in urologic diseases and cancer.
2019 Accreditation Information

CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Society for Basic Urologic Research, Inc.

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Society for Basic Urologic Research, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for Physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 17.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Americans with Disabilities Act
Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact the SBUR prior to the live event. Contact SBUR for privacy and confidentiality policy statement information at sbur@affinity-strategies.com

Acknowledgement
This activity is supported by an educational grants from Astellas, AstraZeneca, Pfizer, Bristol-Myers Squibb, and Merck & Co., Inc.

THANK YOU TO THE FOLLOWING PARTNERS FOR SPONSORING THE SBUR 2019 ANNUAL MEETING

AMERICAN UROLOGICAL ASSOCIATION, OFFICE OF EDUCATION & RESEARCH, INC.
ASTRAZENECA
ASTELLAS
PFIZER
MERCK & CO., INC.
BRISTOL-MEYERS SQUIBB
NIH NATIONAL CANCER INSTITUTE
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
TULANE UNIVERSITY
Welcome Colleagues and Friends!

Welcome to the Society for Basic Urologic Research (SBUR) 2019 Annual Meeting. We are thrilled to see you all here in beautiful New Orleans!

The SBUR is an organization that brings together basic science researchers and physician-scientists, who are engaged in basic and translational research in urological diseases. This meeting offers a valuable forum for interactions between the basic and clinical disciplines. It exposes bench scientists to clinical challenges, clinicians to scientific developments, and all attendees benefit from learning about the cutting-edge concepts and approaches to enhance their scientific knowledge. Clearly, such focused crosstalk very likely will lead to the rapid development of trans-disciplinary, translational and clinical projects that have enormous benefits to patient care.

The meeting will open with the Trainee Affairs Career Symposium on Thursday, November 7th, led by Drs. Larisa Nonn and Arun Sreekumar. After the Symposium, the annual meeting begins with a Keynote Session highlighting the Leland W.K. Chung Lecture, followed by six Plenary Sessions covering the following topics: 1) Big Data as Engines for Discovery; 2) Targeting Endocrine and Metabolic Dysfunctions; 3) Immunology and Immunotherapy; 4) Targeting Benign Urologic Disease; 5) Innovative Technologies in Urology; and, 6) Microbiome and Inflammation.

We would like to thank the SBUR 2019 Annual Meeting Faculty members as well as Program Committee members for their invaluable assistance in planning this meeting. We are also very grateful for the continued support of Trainee Travel Awards from the National Institute of Health (NIH), National Cancer Institute (NCI) and National Institute of Diabetes and Digestive Kidney Diseases (NIDDK). An unprecedented number of abstract submissions were received this year and we would like to give special thanks to Dr. Jindan Yu for her leadership as Chair of the Abstracts Travel Award Selection (ATAS) Committee.

Thanks again for joining us at the New Orleans Downtown Marriott at the Convention Center. We hope you enjoy vibrant New Orleans and you find the presentations and discussions during our scientific program to be helpful and meaningful for your research and collaborations back home.

Allen C. Gao, MD, PhD
President, SBUR

Zongbing You, MD, PhD
Chair, 2019 Annual Meeting Program Committee
# TABLE OF CONTENTS

- CME Information ................................................................. pg 07
- SBUR Committees ............................................................... pg 08
- Award Winners ..................................................................... pg 10
- Faculty Listing ...................................................................... pg 12
- Thursday Schedule ............................................................. pg 14
- Friday Schedule ..................................................................... pg 16
- Saturday Schedule ............................................................. pg 19
- Sunday Schedule ............................................................... pg 22
- Travel Award Podium Presentations ...................................... pg 24
- Poster Session 1 ................................................................. pg 32
- Poster Session 2 ................................................................. pg 44
- New Orleans Marriott Hotel Information .............................. pg 55
- 2020 SBUR Meetings ........................................................... pg 56
GENERAL INFORMATION

Registration Hours
_Fleur de Lis Foyer_
Thursday, November 7..................................................................................................................2:00pm–8:30pm
Friday, November 8 .......................................................................................................................7:00am–6:00pm
Saturday, November 9 ...................................................................................................................7:00am–6:00pm
Sunday, November 10 .....................................................................................................................7:00am–12:00pm

General Session
_Blaine Kern Ballroom_
Thursday, November 7 ...................................................................................................................3:00pm–8:00pm
Friday, November 8 .......................................................................................................................8:00am–5:15pm
Saturday, November 9 ...................................................................................................................8:00am–5:00pm
Sunday, November 10 .....................................................................................................................8:00am–12:00pm

Trainee Affairs Career Symposium
_Blaine Kern Ballroom_
Thursday, November 7 ...................................................................................................................3:00pm–5:00pm

Lunch
_River Bend Ballroom_
Friday, November 8 .......................................................................................................................12:00pm–1:30pm
Saturday, November 9 ...................................................................................................................12:30pm–2:00pm

Evening Events
_Blaine Kern Ballroom Foyer, Blaine Kern Ballroom, Magnolia, Fleur de Lis_
Welcome Reception
Thursday, November 7 ...................................................................................................................8:00pm–9:00pm
Poster Session 1
Friday, November 8 ..........................................................................................................................5:15pm–7:15pm
Trainee Affairs Dinner
Friday, November 8 ..........................................................................................................................7:15pm
At Registered Attendee’s Expense. Attendees MUST visit Registration Desk to RSVP and receive restaurant assignment.
Poster Session 2
Saturday, November 9 ....................................................................................................................5:00pm–7:00pm
Criteria for Success

Statements of credit will be awarded based on the participant's attendance and submission of the online activity evaluation form. Upon submission of the evaluation form, a certificate will generate for printing and a copy is sent to your email address. Please click the link below to access the evaluation.

[akhcme.com/akhcme/pages/sbur](akhcme.com/akhcme/pages/sbur)

Please claim your credit by December 15, 2019

If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Society for Basic Urologic Research, Inc.

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Society for Basic Urologic Research, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for Physicians. AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 17.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Commercial Support

This activity is supported by an educational grant from Astellas, AstraZeneca, Pfizer, Bristol-Myers Squibb, and Merck & Co., Inc.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
SBUR 2019 Committees

A large part of our success is a direct result of the incredible work of our committees. If you are interested in learning more about our various committees or participating on a committee, please email sbur@affinity-strategies.com

**Abstracts and Travel Award Selection (ATAS) Committee**
Jindan Yu, PhD (Chair)
Zongbing You, MD, PhD (2019 Chair)
Scott Dehm, PhD (2020 Chair)
Jaoti Huang, PhD
David S. Rickman, PhD
Daniel E Frigo, PhD
David Degraff, PhD
Karen Sfanos, MS, PhD
David Goodrich, PhD
Jill A Macoska, PhD
Jelani Zarif, MS, PhD

**Advocacy Committee (Ad Hoc)**
Magda Grabowska (Chair)
Travis Jerde, PhD (SBUR Secretary) EC member (2019)

**Annual Meeting Program Committee**
Zongbing You, MD, PhD (2019 Chair)
Scott Dehm, PhD (2020 Chair)
Jindan Yu, PhD (2021 Chair)
Marc Cox, PhD (2018 Chair, Advisor)
Amina Zoubeidi, PhD
Christina A.M Jamieson, PhD
Zhou Wang, PhD
Hari K. Koul, MSC, PhD, FASN
Rosalyn Adam, PhD
Allen Gao, MD, PhD, President, ex officio
Ganesh Raj, MD, PhD, Past President, ex officio

**Finance Committee**
Shawn Lupold, PhD, Treasurer (Chair)
Rosalyn Adam, PhD, Vice President
Jindan Yu
Chad Vezina
Zhou Wang

**Mission Urosciences Committee (2018-2019)**
Timothy L. Ratliff, PHD (Chair)
Allen C. Gao, MD, PhD
Ralph Buttyan, PhD
Leland W.K. Chung, PhD
Michael R. Freeman, PhD
Travis J. Jerde, PhD
Hari K. Koul, MSC, PhD, FACN
Natasha Kyprianou, PhD
Vinata B. Lokeshwar, PhD
Gail S. Prins, PhD
Ganesh V. Raj, MD, PhD
Jindan Yu, PhD

**Coffey Award Committee**
Leland W.K. Chung, PhD
Ganesh Raj, MD, PhD
Natasha Kyprianou, PhD
Ken Pienta, MD
Scott Dehm, PhD

**AUA Research Council Representatives**
Allen Gao, MD, PhD, President (2020)
Rosalyn Adam, PhD, Vice President
Ganesh Raj, MD, Past President

**Awards Committee (Ad Hoc)**
Natasha Kyprianou (Chair)
Anna Woloszynska-Read
Douglas Strand
Amina Zoubeidi
Yan Dong

**By-Laws Committee**
Christina Jamison (Chair)
David Degraff
Hannah Heemers
Paramita Ghosh
Donald Vander Griend
SBUR 2019 Committees

Industry Relations/Fundraising Committee (Ad Hoc)
Allen Gao, MD, PhD, EC Member (Chair)
Marc Cox, PhD (2018 Fall Program Chair)
Zongbing You, MD, PhD (2019 Fall Chair)
Natasha Kyprianou, PhD (to 2018)
David Jarrard
Isaac Kim, MD, PhD (to 2018)
Ganesh Raj, MD ex officio EC Member
Mehdi Mollapour
Jun Luo, PhD

Media/Website Committee (Ad Hoc)
Magda Grabowska (Chair)
Bethany Kerr (Vice Chair)
Minhaj Siddiqui
Tanya Stoyanova
Karen Sfanos
Dan Frigo
Jenn Doll

Membership Committee
Travis Jerde, PhD (SBUR Secretary) EC member (2019)
Scott Dehm, PhD
Benyi Li, MD, PhD (2019)
Xiaoqi Liu, PhD
Anna Malykhina, PhD, Chair (2019)
Magaly Martinez-Ferrer, PhD
Shailesh Singh, PhD
Praveen Thumblakat, PhD
Li Xin, PhD
Xiaolin Zi, PhD
Minhaj Siddiqui
Chris Barbieri
Sanjay Gupta

Nominating Committee
Ganesh Raj, MD, Past President (Chair)
JT Hsieh (2020)
Justin Drake, PhD (2019)
Leigh Ellis, PhD (2019)
Laura Pascal, PhD (2019)
Zongbing You (2020)

Program Committee - Spring 2019 Meeting
Rosalyn Adam, PhD (Chair)
Leigh Ellis, PhD
Madga Grabowska, PhD
Thomas Griffith, PhD
Laura Lamb, PhD
Ganesh Raj, MD, PhD (Past President)

Trainee Affairs Committee (Ad Hoc)
Larisa Nonn (Chair)
Arun Sreekumar, Co-Chair (2020 Chair)
Sean Li, Faculty (2020 Co-Chair)
Tara McCray, Trainee-student
Tariq Khemees, Trainee-MD
Renee Vickman, Trainee-Postdoc
Alan Lombard, Trainee-Postdoc
Leigh Ellis, Faculty

Publications Committee
Natasha Kyprianou, PhD
Simon Hayward, PhD
Thomas S. Griffith, PhD
Tanya Stoyanova, PhD
David J. DeGraff, PhD
Ralph Buttyan, PhD
Hari Koul, PhD
Roberto Pili, PhD
Mehdi Mollapour, PhD
Dale Bjorling, PhD
Vinata Lokeshwar, PhD
Gail Prins, PhD
Dorris Lamb, PhD
Carol Podlasek, PhD
Margot Damaser, PhD
Jindan Yu, PhD
Arun Sreekumar, PhD
Sean Li, PhD
Joshua Mauney, PhD
Ganesh Raj, MD, PhD
Isaac Kim, MD, PhD
K.C Balaji, MD
Benyi Li, MD, PhD
James L. Mohler, MD
Tom F. Lue, MD
Congratulations to the 2019 SBUR Award Winners

**Distinguished Service Award**
Presented annually at the Fall Meeting, this award recognizes a member who has helped SBUR with his/her services and/or influences.

**Gail S. Prins, PhD**
University of Illinois at Chicago

**Meritorious Achievement Award**
Presented annually at the Fall Meeting, this award recognizes a researcher (can be a clinician researcher) who has made exceptional contributions in the field of urologic research.

**Dan Theodorescu, MD, PhD**
Cedar-Sinai

**SWIU/SBUR Award for Excellence in Urologic Research**
SWIU and SBUR have a common interest in recognizing female scientists with an accomplished background of basic science urologic research. The award represents the collaborative efforts of these two societies toward their common goal.

**Kerry L. Burnstein, PhD**
University of Miami

**Young Investigator Award Recipients**
The SBUR Young Investigator Awards are presented at the Fall Meeting to SBUR members under the age of 45, within 5 years of their first faculty position, who have made significant contributions to urologic research.

**Ping Mu, PhD**
UT Southwestern

**Bethany Kerr, PhD**
Wake Forest University

**Andrew Goldstein, PhD**
UCLA

**Eula and Donald S. Coffey Innovative Research Award Finalists**
The Eula and Donald S. Coffey Innovative Research Award will be presented to the most innovative abstract at the SBUR Fall Annual Meeting. The top 3 finalists are asked to give a brief oral presentation of their research findings to open the Awards Presentations. The winner will be announced at the Saturday Awards Ceremony.

**John K. Lee, MD, PhD**
Fred Hutchinson Cancer Research Center

**Xin Lu, PhD**
University of Notre Dame

**Salma Kaochar, PhD**
Baylor College of Medicine
**Travel Award Winners**

A primary goal of SBUR is to provide travel grants/stipends to researcher trainees. These grants support travel to/from the Fall Annual Meeting. Award recipients must be SBUR members and a recipient is not allowed to receive the award in two consecutive years.

**Diya Binoy Joseph**  
UT Southwestern Medical Center

**Ka-Wing Fong**  
Northwestern University

**Wanting Han**  
University of Massachusetts Boston

**Petra Popovics**  
University of Wisconsin-Madison

**Ahmed A. Moustafa**  
Tulane University

**Teresa T Liu**  
University of Wisconsin-Madison

**Nicholas Brady**  
Weill Cornell Medicine

**Jenna M. Buckwalter**  
Penn State Hershey College of Medicine

**Cameron Armstrong**  
UC Davis

**Dongxia Ge**  
Tulane University

**Liang Wang**  
University of California, Los Angeles

**Sarah Kohrt**  
Case Western Reserve University

**Mathilde Bonnemaison**  
University of Massachusetts Boston

**Yang Yi**  
Northwestern University

**Anindita Ravindran**  
Baylor College of Medicine

**Elena Beketova**  
Purdue University

**Victor Pham**  
University of California, Irvine

**Qin Gao**  
University of Texas at El Paso

**Shih-Bo Huang**  
University of Texas Health Science Center at San Antonio

**Praveen Kumar Jaiswal**  
Louisiana State University Health Science Center-Shreveport
Thank You to the 2019 SBUR Distinguished Faculty

Larisa Nonn, PhD
Trainee Affairs Committee Chair
University of Illinois at Chicago
Chicago, IL

Arun Sreekumar, PhD
Trainee Affairs Committee Co-Chair
Baylor College of Medicine
Houston, TX

Allen Gao, MD, PhD
SBUR President
University of California at Davis
Davis, CA

Zongbing You, MD, PhD
Tulane University
New Orleans, LA

Travis J. Jerde, PhD
Indiana University
Indianapolis, IN

Arul M. Chinnaiyan, M.D., Ph.D.
University of Michigan
Ann Arbor, MI

Oliver Sartor, MD
Tulane University
New Orleans, LA

Chang-Deng Hu, MD, PhD
Purdue University
West Lafayette, IN

Jindan Yu, PhD
Northwestern University
Chicago, IL

Sooryanarayana Varambally, PhD
University of Alabama-Birmingham
Birmingham, AL

Vinata B. Lokeshwar, PhD
Augusta University
Augusta, GA

Shawn E. Lupold, PhD
Johns Hopkins Hospital
Baltimore, MD

Kaifu Chen, PhD
Houston Methodist
Houston, TX

Rosalyn Adam, PhD
SBUR Vice President
Boston Children’s Hospital and Harvard Medical School
Boston, MA

Qianben Wang, PhD
Duke University
Durham, NC

Gail S. Prins, PhD
University of Illinois at Chicago
Chicago, IL

Benyi Li, MD, PhD
University of Kansas Medical Center
Kansas, KS

Hsing-Jien Kung, PhD
Taipei Medical University
Taiwan, ROC

Jiaoti Huang, MD, PhD
Duke University
Durham, NC

Hari K. Koul, MSC, PhD, FASN
Louisiana State University Health Science Center-Shreveport
Shreveport, LA

Yun Qiu, PhD
University of Maryland
Baltimore, MD

Carolyn Best, PhD
American Urological Association
Linthicum, MD

Joel B. Nelson, MD
University of Pittsburgh
Pittsburgh, PA

Timothy L. Ratliff, PhD
Purdue University Center for Cancer Research
West Lafayette, IN
Yan Dong, PhD
Tulane University
New Orleans, LA

William Ricke, PhD
University of Wisconsin School of Medicine and Public Health
Madison, WI

Indira U. Mysorekar, PhD
Washington University
St. Louis, MO

Simon W. Hayward, PhD
NorthShore University HealthSystem
Evanston, IL

Sanjay Gupta, Ph.D.
Case Western Reserve University
Cleveland, OH

Li Jia, PhD
Brigham and Women’s Hospital
Boston, MA

Asim B. Abdel-Mageed, DVM, PhD
Tulane University
New Orleans, LA

Joshua J. Meeks, MD, PhD
Northwestern University
Chicago, IL

Ganesh V. Raj, MD, PhD
Immediate Past SBUR President
UT Southwestern Medical Center
Dallas, TX

Amina Zoubeidi, PhD
University of Vancouver
Vancouver, British Columbia, Canada

Michelle Downes MB BCh BAO, MRCSI, MD, FRCPC
Sunnybrook Health Sciences Centre
Toronto, ON, Canada

Tamara Bavendam, MD
NIDDK/NIH
Bethesda, MD

Jonathan Barasch, MD, PhD
Columbia University O’Brien Center
New York, NY

Zhou Wang, PhD
University of Pittsburgh
Pittsburgh, PA

Thomas Chi, MD (PI: P20 Program)
University of California at San Francisco
San Francisco, CA

Marc B. Cox, MSPH, PhD
University of Texas at El Paso
El Paso, TX

Paramita Mitra Ghosh, PhD
University of California at Davis
Davis, CA

Karen S. Sfanos, Ph.D.
Johns Hopkins Hospital
Baltimore, MD

Angelo M. De Marzo, MD, PhD
Johns Hopkins Hospital
Baltimore, MD

Michael A. Liss, MD
University of Texas Health Science Center
San Antonio, TX

Zoran Culig, MD
Innsbruck Medical University
Innsbruck, Austria

Praveen Thumbikat, PhD
Northwestern University
Chicago, IL

Jin Zeng, MD, PhD
The First Affiliated Hospital of Xi’an Jiaotong University
Xi’an, China

Wade Bushman, M.D., Ph.D.
University of Wisconsin Medical School
Madison, WI

Jill A. Macoska, PhD
University of Massachusetts Boston
Boston, MA

Xiaoqi Liu, PhD
University of Kentucky
Lexington, KY
Thursday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00pm–8:30pm</td>
<td>Registration</td>
<td></td>
</tr>
</tbody>
</table>
| 3:00pm–5:00pm | Trainee Affairs Career Symposium           | Larisa Nonn, PhD
Trainee Affairs Committee Chair
University of Illinois at Chicago
Chicago, IL
Arun Sreekumar, PhD
Trainee Affairs Committee Co-Chair
Baylor College of Medicine
Houston, TX

Career Symposium Speaker:

**Group 1**
Laura Pascal, PhD
Research Assistant Professor
University of Pittsburgh
Pittsburgh, PA

Trivia Frazier, PhD
President and CEO
Obatala Sciences, Inc
New Orleans, LA

**Group 2**
Magda Grabowska, PhD
Assistant Professor
Case Western Reserve University
Cleveland, OH

Tim Ratliff, PhD
Professor
Purdue University
West Lafayette, IN

Adam Murphy, MD
Assistant Professor
Northwestern University
Chicago, IL

**Group 3**
Gail Prins, PhD
Professor
University of Illinois at Chicago
Chicago, IL

Moray Campbell, PhD
Associate Professor
Ohio State Comprehensive Cancer Center
Columbus, OH

**Group 4**
Tamara Bavendam, MD
NIDDK/NIH
Bethesda, MD

Larisa Nonn, PhD
University of Illinois at Chicago
Chicago, IL

Chad Vezina, PhD
University of Wisconsin at Madison
Madison, WI
## Thursday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Details</th>
</tr>
</thead>
</table>
| 6:00pm–6:10pm     | Welcome & Introductory Remarks                  | Allen Gao, MD, PhD  
                     |                                  | SBUR President  
                     |                                  | University of California at Davis  
                     |                                  | Davis, CA                        |
| 6:10pm–8:00pm     | Keynote Session                                 | **Discussion Leaders:**  
                     |                                  | Zongbing You, MD, PhD  
                     |                                  | Tulane University  
                     |                                  | New Orleans, LA                   |
|                   |                                                 | Travis J. Jerde, PhD  
                     |                                  | Indiana University  
                     |                                  | Indianapolis, IN                  |
| 6:10pm–7:10pm     | Leland W.K. Chung Lecture                       | **Fast, Furious, and Loud: The Role of FOXA1 in Prostate Cancer Progression**  
                     |                                  | Arul M. Chinnaiyan, M.D., Ph.D.  
                     |                                  | Director, Michigan Center for Translational Pathology  
                     |                                  | S.P. Hicks Endowed Professor of Pathology and Urology  
                     |                                  | American Cancer Society Research Professor  
                     |                                  | Investigator, Howard Hughes Medical Institute  
                     |                                  | Comprehensive Cancer Center  
                     |                                  | University of Michigan  
                     |                                  | Ann Arbor, MI                     |
| 7:10pm–7:25pm     | Discussion                                      | **Arul M. Chinnaiyan, M.D., Ph.D.** is a Howard Hughes Medical Institute Investigator, American Cancer Society Research Professor, and S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan. He is also a member of the University of Michigan Rogel Cancer Center. He is the founding Director of the Michigan Center for Translational Pathology (MCTP) which is comprised of a multidisciplinary team of investigators focused on translating “Omic” technologies to patient care in terms of biomarkers and novel therapeutics. He has co-authored over 450 manuscripts and has been designated an A. Alfred Taubman Medical Research Institute Scholar, is an elected member of the American Academy of Arts and Sciences (AAAS), the National Academy of Medicine, the Association of American Physicians (AAP), the American Society for Clinical Investigation (ASCI), and the National Academy of Inventors (NAI). He serves on the Board of Scientific Advisors for the National Cancer Institute.  
                     |                                  | In addition to receiving his undergraduate degree and medical training at Michigan, he received his Ph.D. in Pathology and has made seminal contributions to the understanding of the molecular mechanisms of how cells die (a process called apoptosis). Dr. Chinnaiyan has received a number of awards including the Basic Science Research Award awarded by the University of Michigan Medical School Dean’s Office, the AMGEN Outstanding Investigator Award, the Pew Biomedical Scholar Award, the Burroughs Welcome Foundation Award in Clinical Translational Research, the 2006 Benjamin Castleman Award, the 2007 Ramzi Cotran Young Investigator Award and was recently appointed as an Investigator of the Howard Hughes Medical Institute. Dr. Chinnaiyan was also elected as a member of the American Society of Clinical Investigation and the Association of American Physicians.  |

| 7:10pm–7:25pm     | Discussion                                      | Arul M. Chinnaiyan, M.D., Ph.D. is a Howard Hughes Medical Institute Investigator, American Cancer Society Research Professor, and S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan. He is also a member of the University of Michigan Rogel Cancer Center. He is the founding Director of the Michigan Center for Translational Pathology (MCTP) which is comprised of a multidisciplinary team of investigators focused on translating “Omic” technologies to patient care in terms of biomarkers and novel therapeutics. He has co-authored over 450 manuscripts and has been designated an A. Alfred Taubman Medical Research Institute Scholar, is an elected member of the American Academy of Arts and Sciences (AAAS), the National Academy of Medicine, the Association of American Physicians (AAP), the American Society for Clinical Investigation (ASCI), and the National Academy of Inventors (NAI). He serves on the Board of Scientific Advisors for the National Cancer Institute.  
                     |                                  | In addition to receiving his undergraduate degree and medical training at Michigan, he received his Ph.D. in Pathology and has made seminal contributions to the understanding of the molecular mechanisms of how cells die (a process called apoptosis). Dr. Chinnaiyan has received a number of awards including the Basic Science Research Award awarded by the University of Michigan Medical School Dean’s Office, the AMGEN Outstanding Investigator Award, the Pew Biomedical Scholar Award, the Burroughs Welcome Foundation Award in Clinical Translational Research, the 2006 Benjamin Castleman Award, the 2007 Ramzi Cotran Young Investigator Award and was recently appointed as an Investigator of the Howard Hughes Medical Institute. Dr. Chinnaiyan was also elected as a member of the American Society of Clinical Investigation and the Association of American Physicians. |
## Thursday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:25pm–7:50pm</td>
<td>Prostate Cancer Update 2019: From Genetics to Clinical Trials</td>
<td>Oliver Sartor, MD Tulane University New Orleans, LA</td>
</tr>
<tr>
<td>7:50pm–8:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:00pm–9:00pm</td>
<td>Welcome Reception and Networking</td>
<td></td>
</tr>
</tbody>
</table>

## Friday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am–12:00pm</td>
<td>Plenary Session I: Big Data as Engines for Discovery</td>
<td>Discussion Leaders:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chang-Deng Hu, MD, PhD Purdue University West Lafayette, IN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jindan Yu, PhD Northwestern University Chicago, IL</td>
</tr>
<tr>
<td>8:00am–8:20am</td>
<td>UALCAN: an Integrated Data Mining Platform for Comprehensive Analysis of Cancer Transcriptome and Novel Target Discovery</td>
<td>Sooryanarayana Varambally, PhD University of Alabama-Birmingham Birmingham, AL</td>
</tr>
<tr>
<td>8:20am–8:30am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:30am–8:50am</td>
<td>Molecular Subtypes Chase in Bladder Cancer</td>
<td>Vinata B. Lokeshwar, PhD Augusta University Augusta, GA</td>
</tr>
<tr>
<td>8:50am–9:00am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:00am–9:20am</td>
<td>The Role of miR-21 in Prostate Cancer Development and Progression</td>
<td>Shawn E. Lupold, PhD Johns Hopkins Hospital Baltimore, MD</td>
</tr>
<tr>
<td>9:20am–9:30am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:30am–9:40am</td>
<td>Travel Award Presentation #1: PRMT5 as a Novel Target for the Treatment of Castration-resistant Prostate Cancer</td>
<td>Elena Beketova Purdue University West Lafayette, IN</td>
</tr>
<tr>
<td>9:40am–9:45am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:45am–10:00am</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
## Friday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am–10:20am</td>
<td>Epigenetic Landscape Reveals Druggable Driver Genes for Tumorigenesis</td>
<td>Kaifu Chen, PhD Houston Methodist Houston, TX</td>
</tr>
<tr>
<td>10:20am–10:30am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:30am–10:40am</td>
<td>Travel Award Presentation 2: N-Myc-mediated Epigenetic Reprogramming Drives Lineage Plasticity in Advanced Prostate Cancer</td>
<td>Nicholas Brady, PhD Weill Cornell Medicine New York, NY</td>
</tr>
<tr>
<td>10:40am–10:45am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:45am–11:05am</td>
<td>Probing the Transcriptional Landscape of the Bladder Following Spinal Cord Injury</td>
<td>Rosalyn Adam, PhD SBUR Vice President Boston Children’s Hospital and Harvard Medical School Boston, MA</td>
</tr>
<tr>
<td>11:05am–11:15am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:15am–11:35am</td>
<td>Epigenomic Approaches to Discover Transcriptional Vulnerabilities of Prostate Cancer</td>
<td>Qianben Wang, PhD Duke University Durham, NC</td>
</tr>
<tr>
<td>11:35am–11:45am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:45am–11:55am</td>
<td>Travel Award Presentation 3: Site Specific DNA Methylation Silences Forkhead Box A1 Expression in Advanced Bladder Cancer</td>
<td>Jenna M. Buckwalter, PhD Penn State College of Medicine Hershey, PA</td>
</tr>
<tr>
<td>11:55am–12:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:00pm–1:30pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:30pm–5:15pm</td>
<td>Plenary Session II: Targeting Endocrine and Metabolic Dysfunctions</td>
<td>Discussion Leaders:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gail S. Prins, PhD University of Illinois at Chicago Chicago, IL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Benyi Li, MD, PhD University of Kansas Medical Center Kansas, KS</td>
</tr>
<tr>
<td>1:30–1:50pm</td>
<td>Targeting Metabolic Addiction of Prostate Cancer</td>
<td>Hsing-Jien Kung, PhD Taipei Medical University Taiwan, ROC</td>
</tr>
<tr>
<td>1:50pm–2:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>2:00pm–2:20pm</td>
<td>Hormonal Therapy for Prostate Cancer: Metabolic Changes as the Molecular Basis of Treatment Response and Failure</td>
<td>Jiaoti Huang, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:20pm–2:30pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>2:30pm–2:50pm</td>
<td>PDEF Alters the Enhancer Landscape to Promote Prostate Luminal Differentiation</td>
<td>Hari K. Koul, MSC, PhD, FASN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:50pm–3:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:00pm–3:10pm</td>
<td>Travel Award Presentation #4: Identification of a Novel PRC2 Complex as a Therapeutic Target in Castration Resistant Prostate Cancer</td>
<td>Ka-Wing Fong, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:10pm–3:15pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:15pm–3:30pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:30pm–3:50pm</td>
<td>The Role of Crosstalk between AR and E2F in Prostate Cancer Therapeutic Resistance</td>
<td>Yun Qiu, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:50pm–4:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>4:00pm–4:20pm</td>
<td>Polo-like Kinase 1: From Cell Biology to Cancer Therapeutics</td>
<td>Xiaojie Liu, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:20pm–4:30pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>4:30pm–4:40pm</td>
<td>Travel Award Presentation #5: A Preclinical Study of the Combination Treatment of High-dose Testosterone and CDK4/6 Inhibitors in CRPC</td>
<td>Wanting Han</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40pm–4:45pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>4:45pm–4:55pm</td>
<td>Travel Award Presentation #6: Targeting Steroid Sulfatase with Novel Inhibitors Suppresses CRPC Tumor Growth and Improves Response to Enzalutamide</td>
<td>Cameron Armstrong, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:55pm–5:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Friday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00pm–5:15pm</td>
<td>AUA Office of Research: Update on Urologic Research Support Opportunities</td>
</tr>
<tr>
<td></td>
<td>Carolyn Best, PhD</td>
</tr>
<tr>
<td></td>
<td>American Urological Association</td>
</tr>
<tr>
<td></td>
<td>Linthicum, MD</td>
</tr>
<tr>
<td>5:15pm–7:15pm</td>
<td>Poster Session #1</td>
</tr>
<tr>
<td>7:15pm</td>
<td>Evening on Own</td>
</tr>
<tr>
<td>7:15pm</td>
<td>Trainee Affairs Group Dinner</td>
</tr>
</tbody>
</table>

Saturday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am–10:00am</td>
<td>Plenary Session III: immunology and Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Discussion Leaders:</td>
</tr>
<tr>
<td></td>
<td>Marc B. Cox, MSPH, PhD</td>
</tr>
<tr>
<td></td>
<td>University of Texas at El Paso</td>
</tr>
<tr>
<td></td>
<td>El Paso, TX</td>
</tr>
<tr>
<td></td>
<td>Amina Zoubaidi, PhD</td>
</tr>
<tr>
<td></td>
<td>University of Vancouver</td>
</tr>
<tr>
<td></td>
<td>Vancouver, British Columbia, Canada</td>
</tr>
<tr>
<td>8:00am–8:50am</td>
<td>AUA Lecture</td>
</tr>
<tr>
<td></td>
<td>Prostate Cancer Revisited</td>
</tr>
<tr>
<td></td>
<td>Joel B. Nelson, MD</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh</td>
</tr>
<tr>
<td></td>
<td>Pittsburgh, PA</td>
</tr>
</tbody>
</table>

Joel B. Nelson received a BA in Philosophy at the University of Pittsburgh in 1983. He received his medical degree in 1988 and completed his urology residency in 1994, both at Northwestern University Medical School. He was awarded an American Foundation for Urological Disease Scholarship for fellowship training in basic research and oncology at the Brady Urological Institute at Johns Hopkins from 1994 to 1996. After joining the faculty of the Department of Urology at Johns Hopkins in 1996, Dr. Nelson was named the Director of Urological Oncology at Johns Hopkins Bayview Medical Center. In 1999, Dr. Nelson was appointed the first Frederic N. Schwentker Professor and first Chairman of the newly formed Department of Urology at the University of Pittsburgh School of Medicine. Under his leadership, the Department has grown from five to over 40 full-time faculty members, with a several-fold increase in clinical volumes and research funding, placing it in the top ten for NIH funding. Dr. Nelson’s area of clinical interest is focused on prostate cancer and he has performed over 3300 radical prostatectomies. His research interest has been on novel treatments for advanced prostate cancer. Dr. Nelson has over 220 publications and chapters and is a member of several editorial boards. He is the member of the American Association of Genitourinary Surgeons, the Clinical Society of Genitourinary Surgeons and is a Trustee of the American Board of Urology. Dr. Nelson is the recipient of many clinical and basic science awards. In October 2014, he was appointed Senior Medical Director of the University of Pittsburgh Physicians and in January 2017, Chief Clinical Officer, Health Services Division, UPMC.

8:50am–9:00am | Discussion
## Saturday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00am–9:20am</td>
<td>Defining Inflammation in BPH</td>
<td>Timothy L. Ratliff, PhD&lt;br&gt;Purdue University Center for Cancer Research&lt;br&gt;West Lafayette, IN</td>
</tr>
<tr>
<td>9:20am–9:30am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:30am–9:50am</td>
<td>Bladder Cancer, Inflammation and PD-L1: Where Are We Now?</td>
<td>Michelle Downes, MB BCh BAO, MRCSI, MD, FRCPC&lt;br&gt;Sunnybrook Health Sciences Centre&lt;br&gt;Toronto, ON, Canada</td>
</tr>
<tr>
<td>9:50am–10:00am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00am–10:15am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:15am–12:45pm</td>
<td>Plenary Session IV: Targeting Benign Urologic Disease</td>
<td><strong>Discussion Leaders:</strong>&lt;br&gt;Rosalyn Adam, PhD&lt;br&gt;SBUR Vice President&lt;br&gt;Boston Children’s Hospital and Harvard Medical School&lt;br&gt;Boston, MA&lt;br&gt;&lt;br&gt;Yan Dong, PhD&lt;br&gt;Tulane University&lt;br&gt;New Orleans, LA</td>
</tr>
<tr>
<td>10:15am–10:30am</td>
<td>NIDDK Support of Basic Research for Benign Urologic Conditions</td>
<td>Tamara Bavendam, MD&lt;br&gt;NIDDK/NIH&lt;br&gt;Bethesda, MD</td>
</tr>
<tr>
<td>10:30am–10:45am</td>
<td></td>
<td>William Ricke, PhD&lt;br&gt;Director, O’Brien Center for Benign Urologic Research&lt;br&gt;University of Wisconsin School of Medicine and Public Health&lt;br&gt;Madison, WI</td>
</tr>
<tr>
<td>10:45am–11:00am</td>
<td></td>
<td>Jonathan M. Barasch, MD, PhD&lt;br&gt;Columbia University O’Brien Center&lt;br&gt;New York, NY</td>
</tr>
<tr>
<td>11:00am–11:15am</td>
<td></td>
<td>Zhou Wang, PhD&lt;br&gt;Director, O’Brien Urology Research Center&lt;br&gt;University of Pittsburgh&lt;br&gt;Pittsburgh, PA</td>
</tr>
<tr>
<td>11:15am–11:30am</td>
<td></td>
<td>Discussion</td>
</tr>
</tbody>
</table>
# Saturday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30am–11:45am</td>
<td>Mechanisms of Age-associated Immune Dysfunction in the Post-menopausal Bladder</td>
<td>Indira U. Mysorekar, PhD Washington University St. Louis, MO</td>
</tr>
<tr>
<td>11:45am–12:00pm</td>
<td>ReSKU: an Automated Nephrolithiasis Registry as a Community Research Tool</td>
<td>Thomas Chi, MD University of California at San Francisco San Francisco, CA</td>
</tr>
<tr>
<td>12:00pm–12:15pm</td>
<td>Leukocytic Phenotypes Associated with BPH Progression</td>
<td>Simon W. Hayward, PhD NorthShore University HealthSystem Evanston, IL</td>
</tr>
<tr>
<td>12:15pm–12:30pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:30pm–2:00pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>2:00pm–3:45pm</td>
<td>Plenary Session V: Innovative Technologies in Urology</td>
<td>Discussion Leaders:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ganesh V. Raj, MD, PhD UT Southwestern Medical Center Dallas, TX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paramita Mitra Ghosh, PhD University of California at Davis Davis, CA</td>
</tr>
<tr>
<td>2:00pm–2:20pm</td>
<td>Combining Tissue Histomorphometry and Biomarkers for Precise Prediction of Prostate Cancer Recurrence</td>
<td>Sanjay Gupta, Ph.D. Case Western Reserve University Cleveland, OH</td>
</tr>
<tr>
<td>2:20pm–2:30pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>2:30pm–2:50pm</td>
<td>PARP Inhibitors in Prostate Cancer Treatment — Beyond DNA Repair</td>
<td>Li Jia, PhD Brigham and Women's Hospital Boston, MA</td>
</tr>
<tr>
<td>2:50pm–3:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:00pm–3:20pm</td>
<td>Repurposed Drugs Targeting Exosomes as Adjuvant Therapies for Prostate Cancer</td>
<td>Asim B. Abdel-Mageed, DVM, PhD Tulane University New Orleans, LA</td>
</tr>
<tr>
<td>3:20pm–3:30pm</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
### Saturday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30pm–3:40pm</td>
<td>Travel Award Presentation #7: Identification of Cognate Proximal Cell Types of the Mouse and Human Prostate and Their Enrichment in Human Benign Prostatic Hyperplasia</td>
<td>Diya Binoy Joseph, PhD UT Southwestern Medical Center Dallas, TX</td>
</tr>
<tr>
<td>3:40pm–3:45pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:45pm–4:00pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:00pm–4:30pm</td>
<td>Awards Presentation</td>
<td>Coffey Research Award Presentations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Travel Awards</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Young Investigator Awards</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SWIU/SBUR Award</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Distinguished Service Award</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meritorious Achievement Award</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coffey Research Award Winner</td>
</tr>
<tr>
<td>4:30pm–5:00pm</td>
<td>SBUR Annual Business Meeting</td>
<td>Members Only</td>
</tr>
<tr>
<td>5:00pm–7:00pm</td>
<td>Poster Session #2</td>
<td></td>
</tr>
<tr>
<td>7:00pm</td>
<td>Evening on Own</td>
<td></td>
</tr>
</tbody>
</table>

### Sunday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Discussion Leaders:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am–12:00pm</td>
<td>Plenary Session VI: Microbiome and Inflammation</td>
<td>Karen S. Sfanos, Ph.D. Johns Hopkins Hospital Baltimore, MD Praveen Thumbikat, PhD Northwestern University Chicago, IL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00am–8:20am</td>
<td>International Speaker</td>
<td>Jin Zeng, MD, PhD Department of Urology</td>
</tr>
<tr>
<td></td>
<td>The New Role of PrLZ in Prostate Cancer by Regulating Autophagy</td>
<td>The First Affiliated Hospital Xi’an Jiaotong University Xi’an, China</td>
</tr>
<tr>
<td>8:20am–8:30am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:30am–8:50am</td>
<td>The Inflammatory Microenvironment and Microbiome in Prostate Cancer</td>
<td>Angelo M. De Marzo, MD, PhD Johns Hopkins Hospital Baltimore, MD</td>
</tr>
<tr>
<td>8:50am–9:00am</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
## Sunday Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00am–9:20am</td>
<td>Microbiome Interactions with Localized Prostate Cancer</td>
<td>Michael A. Liss, MD</td>
<td>University of Texas Health Science Center San Antonio, TX</td>
</tr>
<tr>
<td>9:20am–9:30am</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30am–9:50am</td>
<td>Prostate inflammation, Microbiome and Koch’s Postulates</td>
<td>Wade Bushman, M.D., Ph.D.</td>
<td>University of Wisconsin Medical School Madison, WI</td>
</tr>
<tr>
<td>9:50am–10:00am</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00am–10:10am</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10am–10:30am</td>
<td>Inflammation and Lower Urinary Tract Function: a Volatile Relationship</td>
<td>Jill A. Macoska, PhD</td>
<td>The University of Massachusetts Boston Boston, MA</td>
</tr>
<tr>
<td>10:30am–10:40am</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40am–11:00am</td>
<td>Strategies to Inhibit Androgen Receptor and STAT3 Signaling in Prostate Cancer</td>
<td>Zoran Culig, MD</td>
<td>Innsbruck Medical University Innsbruck, Austria</td>
</tr>
<tr>
<td>11:00am–11:10am</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10am–11:30am</td>
<td>Navigating Immunotherapy Responses in Bladder Cancer: From Mice to Men</td>
<td>Joshua J. Meeks, MD, PhD</td>
<td>Northwestern University Chicago, IL</td>
</tr>
<tr>
<td>11:30am–11:40am</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:40am–11:50am</td>
<td>Travel Award Presentation #8: Osteopontin Exacerbates the Inflammatory Environment in the Prostate</td>
<td>Petra Popovics, PhD</td>
<td>University of Wisconsin–Madison Madison, WI</td>
</tr>
<tr>
<td>11:50am–11:55am</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55am–12:00pm</td>
<td>Farewell</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**2019 Travel Awardees — Podium Presentations**

**Friday, November 9, 2019**
**9:30 – 9:40 a.m.**
**Travel Award Presentation #1:**
**PRMT5 as a Novel Target for the Treatment of Castration-resistant Prostate Cancer**

Elena Beketova  
Purdue University  
West Lafayette, IN

**Background:**  
Emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is one of the biggest challenges in prostate cancer therapy. Androgen receptor (AR) reactivation via various mechanisms is the driver of the ADT resistance. Current CRPC therapies that target AR signaling are not curative and only prolong survival by 4-5 months. Thus, the development of novel approaches for CRPC treatment is in urgent need.

Recently it was shown that protein arginine methyltransferase 5 (PRMT5), an emerging epigenetic enzyme and putative splicing regulator, is required for the hormone-naïve prostate cancer (HNPC) growth. Mechanistically, it was demonstrated that in HNPC PRMT5 epigenetically activates AR transcription. Considering the role of AR in CRPC and that PRMT5 regulates AR in HNPC, we aimed to determine whether PRMT5 regulates AR expression in CRPC.

**Methods:**

shRNA against PRMT5 and inhibitor BLL3.3 were used to target PRMT5 in CRPC cells C4-2 (AR overexpression), 22Rv1 (AR-V7 expression) and VCaP (AR gene amplification). Transcriptome-wide gene expression was measured via RNA-seq. AR and AR target genes expression were analyzed using Western Blot and RT-qPCR. Cell proliferation was measured using MTT assay. Chromatin immunoprecipitation was used to analyze presence of PRMT5 and associated histone methylation marks at the AR promoter. 22Rv1 lines with shRNA inducible expression were established for use in xenograft studies.

**Results:**

PRMT5 targeting reduced cell proliferation and decreased the protein and mRNA levels of both AR full length and V7 in all CRPC cell lines tested. Consistently, expression of full length AR or AR-V7 target genes was decreased. PRMT5 and H4R3me2s were present at the AR promoter. To further explore the role of PRMT5 in CRPC, we performed RNA-seq analysis in 22Rv1 upon PRMT5 knockdown. Interestingly, 293 genes were down- and 329 genes were upregulated upon PRMT5 knockdown contrary to the common perception of PRMT5 as an epigenetic suppressor. Additionally, exon mapping revealed differential up- and down-regulation of AR isoforms in PRMT5 knockdown samples suggesting that PRMT5 regulates AR splicing. PRMT5 knockdown significantly reduced the growth of 22Rv1 xenografts in castrated NRG male mice.

**Conclusions:**

Our results suggest that PRMT5 acts as a regulator of AR expression in CRPC cells via both epigenetic regulation of transcription and mRNA splicing. Based on these findings, we propose that targeting PRMT5 may present a novel treatment approach for CRPC via eliminating AR and its splice variants expression.
Friday, November 8, 2019
10:30 – 10:40 a.m.
Travel Award Presentation #2:
N-Myc-mediated Epigenetic Reprogramming Drives Lineage Plasticity in Advanced Prostate Cancer
Nicholas Brady, PhD
Weill Cornell Medicine
New York, NY

Background:
Despite the development of highly effective androgen receptor (AR)-directed therapies, nearly 37% of prostate cancer patients develop resistance. A further third of these men develop aggressive neuroendocrine prostate cancer (NEPC) for which no effective therapies exist. Lineage plasticity, a process by which differentiated cells lose their identity and acquire an alternative lineage phenotype, has been proposed as a mechanism of resistance to targeted therapies, however, the molecular programs underlying this transformation are poorly understood. We observed that the majority of NEPC and 20% of castration-resistant prostate cancer (CRPC) aberrantly overexpress the transcription factor MYCN (N-Myc). Despite this frequent occurrence, the role of N-Myc in driving lineage plasticity and the epigenetic mechanisms which regulate disease progression remain to be elucidated.

Methods:
We analyzed overall survival and whole transcriptome data from a cohort of over 200 prostate cancer patients. We also assessed epigenetic modifications along with the N-Myc transcriptome, cistrome and chromatin-bound interactome by performing ChIP-seq, RNA-seq and RIME in a combination of mouse models, human prostate cancer cell lines, and NEPC patient-derived organoids following acute and chronic androgen withdrawal. Finally, we used CRISPR-based approaches to modulate the expression of N-Myc-interacting proteins to assess changes in chromatin accessibility by ATAC-seq.

Results:
Expression of N-Myc is correlated with reduced overall survival and NEPC tumors are significantly enriched for stem cell and neural lineage-defining genes. The N-Myc cistrome is androgen-dependent and drives a transcriptional program leading to epithelial plasticity and the acquisition of clinically relevant neural lineage markers. N-Myc interacts with the known AR co-factors HOXB13 and FOXA1 at neural lineage genes. Interestingly, histone marks at these N-Myc-bound, neural lineage genes are epigenetically reprogrammed by EZH2 and can accurately classify prostate cancer patients in our cohort. Finally, chromatin accessibility is altered by N-Myc in a chromobox family-dependent manner, leading to deregulation of gene expression.

Conclusions:
We describe a functional role for N-Myc in driving NEPC, characterized by changes in the N-Myc cistrome and interacting co-factors, as well as reprogramming of the epigenome in an androgen context-dependent manner. Ongoing studies are addressing tumor heterogeneity during lineage plasticity using single cell-based RNA-seq and ATAC-seq approaches and will identify novel actionable targets for future therapeutic interventions.
Introduction and Objective:
Bladder cancer (BC) has significant molecular and morphologic heterogeneity. Transcription factor forkhead box A1 (FOXA1) is required for maintenance of urothelial differentiation, and decreased FOXA1 expression is associated with basal-squamous BC. As basal-squamous BC responds differentially to therapeutic intervention, manipulation of FOXA1 expression to control subtype specification is an attractive concept. The aim of this study was to determine the mechanism(s) responsible for loss of FOXA1 expression in BC.

Methods:
Computational analysis of the TCGA BC study was used to examine the relationship between FOXA1 mutational, copy number and methylation status with gene expression. The UCSC genome browser was used to identify CpG islands in the FOXA1 gene as potential sites of methylation. A PCR-based system for detecting methylated CpG islands was used to determine the methylation status of FOXA1-associated CpG islands in a panel of human BC cell lines. In addition, human basal BC cell lines that fail to express FOXA1 were treated with DNA methyltransferase (DNMT) inhibitors in an effort to influence methylation status and FOXA1 expression.

Results:
Decreased FOXA1 expression is not correlated with mutational status and/or copy number alterations in BC which suggested a role for epigenetic silencing of FOXA1 in basal-squamous BC. Three CpG islands were identified in the FOXA1 which include islands 99, 123, and 143. Analysis of TCGA DNA methylation data identified significant methylation at CpG island 99 (p<0.0009; Wilcoxon rank sum; Bonferroni) relative to normal adjacent control tissue. Methylation analysis for CpG islands in human BC cell lines determined CpG island 99 was methylated specifically in basal-squamous BC cell lines which fail to express FOXA1, while CpG island 143 was unmethylated. CpG island 123 was methylated in all ten cell lines. Treatment of SCaBER and HT1376 basal-squamous BC cell lines with the DNMT inhibitors 5-Aza-2’deoxycytidine and Zebularine individually and in combination increased FOXA1 expression and decreased DNA methylation at CpG island 99.

Conclusions:
Our data indicates site-specific methylation of CpG island 99 is implicated in the repression of FOXA1 expression in human BC and preclinical models. Importantly, FOXA1 methylation is reversed by DNMT inhibitor treatment, thus confirming methylation as an epigenetic regulatory mechanism controlling FOXA1 expression in BC. Our study additionally shows the importance of examining promoter methylation in association with gene expression to determine the functional consequences of epigenetic alterations.
Friday, November 8, 2019
3:00 – 3:10 p.m.
Travel Award Presentation #4:
Identification of a Novel PRC2 Complex as a Therapeutic Target in Castration Resistant Prostate Cancer
Ka-Wing Fong, PhD
Northwestern University
Chicago, IL

Background:
Metastatic castration-resistant prostate cancer (CRPC) is a lethal disease. Understanding the molecular drivers of CRPC will guide the development of targeted therapies. EZH2, the enzymatic subunit of Polycomb repressive complex 2 (PRC2), is one of the most upregulated genes in CRPC. EZH2 catalyzes trimethylation of Histone H3 at Lysine 27 (H3K27me3), a modification that represses target gene expression. A plethora of tumor suppressor genes has been reportedly to be targets of EZH2, and yet how EZH2 is recruited to specific genomic loci in mammals remain unclear.

Methods:
Co-IP and size-exclusive chromatography assays were utilized to study protein-protein interactions. Co-occupancy of histone marks on the chromatin were assessed by biochemical and ChIP-Seq assays. Reprogramming of PRC2 cistromes along with EZH2 transcriptome in human prostate cancer models were examined by next-generation sequencing techniques.

Results:
By proteomic profiling of EZH2-containing complex in prostate cancer cells, we identified a novel PRC2 sub-complex containing PALI1, a recently identified PRC2-associated protein, and G9a, an H3K9me2 demethylase. Further biochemical experiments revealed that PALI1 utilizes different domains to interact with PRC2 and G9a, acting as a scaffold protein that bridges PRC2 with G9a. Importantly, PALI1 is overexpressed in CRPC and this enhances PRC2- G9a interaction. We further demonstrate that PALI1 and G9a are components of a unique PRC2 sub-complex (named PRC2.3), which is distinct from previously reported EPOP-containing PRC2.1 and JARID2-mediated PRC2.2. Genome-wide co-localization of PRC2-catalyzed H3K27me3 and G9a-catalyzed H3K9me2 were detected at the chromatin. PALI1 promotes reprogramming of PRC2 at G9a co-occupied sites, leading to enhanced H3K27me3 modifications and stronger gene repression. Functionally, these genes are critical for cellular development and differentiation. Their repression, in turn, contribute to prostate cancer de-differentiation and oncogenic progression.

Conclusions:
We report a novel PRC2 sub-complex (PRC2.3) in prostate cancer cells, which contains PALI1 and G9a, but not JARID2 and EPOP. PALI is a critical mediator of PRC2 and G9a interaction and its overexpression in CRPC favors PRC2.3 assembly, resulting in a crosstalk between H3K27me3 and H3K9me2 at the chromatin and enhanced epigenetic silencing of cell differentiation genes. Our data suggest PALI1 and G9a as critical regulators of CRPC and promising targets for therapeutic interventions.
Travel Award Presentation #5:
A Preclinical Study of the Combination Treatment of High-dose Testosterone and CDK4/6 Inhibitors in CRPC
Wanting Han
University of Massachusetts Boston
Boston, MA

Background:
High-dose testosterone (high-T) treatment can suppress the growth of castration-resistant prostate cancer (CRPC) in preclinical and clinical trials. While androgen receptor (AR) is known for its transcriptional activation function, it also has repression function on DNA replication and repair genes. Mechanistically, we have demonstrated that AR globally recruits hypophosphorylated retinoblastoma protein (Rb) to DNA replication gene loci and strengthens the activity of Rb-E2F suppressor complex. This finding is consistent with a recent study on castration-resistant LuCaP models, which shows that the most robust molecular phenotype for high-T treatment is the suppression of E2F transcriptional output. It suggests a novel strategy to enhance the efficacy of high-T treatment with CDK4/6 inhibitors, which block Rb hyperphosphorylation. However, recent sequencing studies in CRPC indicate that ~10-15% of tumors have Rb-loss. Therefore, if these patients can be benefitted from high-T treatment or the combination remains to be determined.

Methods:
Lenti-viral Rb silencing and CRISPR/Cas9 knock-out cell lines were created in CRPC cells, and the efficacy of the combination treatment of high-T with a CDK4/6 inhibitor, palbociclib were tested in the xenografts derived from these cell lines and also in LuCaP CRPC models.

Results:
Rb depletion rapidly impaired the AR-mediated transcriptional repression on DNA replication/repair genes and suppression of cell growth. However, high-T treatment still suppresses the expression of DNA replication genes and cell growth even when Rb is completely knocked out, both in vitro and in vivo. These findings suggest that Rb is contributing but not absolutely required for AR repression activity on DNA replication/repair. Significantly, we found that the interaction of E2F1 and a Rb-like pocket protein p130 was enhanced in Rb knock-out cells and this interaction was dependent on the phosphorylation status of p130, suggesting p130 may function as a substitute of Rb in Rb-loss CRPC cells. For the combination treatment, we found that palbociclib can enhance the efficacy of high-T treatment in cell line and xenograft models. However, this enhancing effect of palbociclib appeared to be dependent on the expression of Rb as it can be only seen in the Rb-positive but not Rb-silenced models.

Conclusions:
Our study provides some new insights into the molecular basis of high-T treatment in CRPC. It suggests that high-T treatment can be used even in Rb-null CRPC. However, the synergistic effect of the combination treatment of high-T and CDK4/6 inhibitors is still dependent on the expression of Rb in CRPC cells.
Travel Award Presentation #6:
Targeting Steroid Sulfatase with Novel Inhibitors Suppresses CRPC Tumor Growth and Improves Response to Enzalutamide
Cameron Armstrong, PhD
University of California Davis
Davis, CA

Background:
Steroid sulfatase (STS) catalyzes the hydrolysis of DHEAS to biologically active DHEA, which is further metabolized to active androgens that bind the androgen receptor (AR) leading to cell proliferation. DHEAS is the most abundant steroid in blood circulation and significant concentrations of DHEAS are present in prostate cancer patients even after ketoconazole or abiraterone therapy, suggesting that this may act as a depot for downstream androgen production. Currently the role of STS in AR signaling and CRPC is largely unknown. This study determines the role of STS in AR signaling and explores the potential of targeting STS to overcome castration resistance in prostate cancer.

Methods:
Quantitative rt-PCR and Western blots were used to detect expression of STS and AR. STS was downregulated using siRNA specific to STS. Stable cell lines overexpressing STS were generated and characterized. RNA-seq was performed on the stable clones to determine alterations in gene expression instigated by STS expression. The steroid profiles of the cells were analyzed by LC-MS using the Thermo Scientific Vanquish UPLC/AB Sciex Qtrap system. STS activity was determined by 4-Methylumbelliferyl sulfate assay. Eleven potent STS inhibitors (SI) were synthesized and characterized. Prostate cancer cell sensitivity to SI was tested using cell growth assays and clonogenic assays. Efficacy of two SI was tested in vivo in castration relapsed VCaP xenograft tumor models.

Results:
STS is overexpressed in CRPC patients and resistant prostate cancer cells including VCaP and C4-2B MDVR. Stable STS overexpression in C4-2B and LNCaP cells increases the levels of testosterone and DHT, respectively. This resulted in increased cell growth and PSA expression in vitro. Inhibiting STS with siRNA suppresses cell growth and AR signaling. Furthermore, STS overexpression in C4-2B and LNCaP cells promoted resistance to enzalutamide and this could be reversed by STS siRNA. Of the 11 potential novel SI, SI-1 and SI-2 were the most potent inhibitors of STS activity and growth in VCaP cells. They significantly suppressed AR transcriptional activity, suggesting that inhibition of STS activity by SI downregulates AR signaling. SI-1 and SI-2 significantly suppressed the growth of relapsed VCaP cells and tumors and improved enzalutamide treatment in vitro and in vivo.

Conclusions:
STS is involved in castration resistance prostate cancer and inhibition of this enzyme could be a viable strategy to treat CRPC and improve enzalutamide treatment.
Saturday, November 9, 2019
3:30 – 3:40 p.m.
Travel Award Presentation #7:
Identification of Cognate Proximal Cell Types of the Mouse and Human Prostate and Their Enrichment in Human Benign Prostatic Hyperplasia
Diya Binoy Joseph, PhD
UT Southwestern Medical Center
Dallas, TX

Background:
Benign prostatic hyperplasia (BPH) is highly prevalent in aging men and poses a significant healthcare burden associated with the treatment of Lower Urinary Tract Symptoms (LUTS). BPH/LUTS remain difficult to treat because of phenotypic heterogeneity, resulting in the need for surgical intervention. The cell types that originate BPH growth are not known. Anatomical studies have shown that the transition zone located near the urethra is the site of BPH growth. We previously identified two novel cell types, club and hillock, that are enriched in the prostatic urethra and proximal ducts. Here, we identify a new proximal fibroblast in the human as well as cognate hillock epithelia and proximal fibroblasts in the mouse. We assess the contribution of each proximal cell type in human BPH, establishing a new paradigm for urethral epithelia and proximal fibroblasts in discrete BPH phenotypes.

Methods:
We used an unbiased approach by single cell RNA-sequencing (scRNA-seq) to identify cognate cell types of the mouse and human prostate and develop new flow cytometry and IHC antibody panels to purify and locate each cell type. The frequency of proximal fibroblasts and urethral epithelia in BPH vs. normal human prostate was assessed using scRNA-seq, flow cytometry, and immunofluorescence.

Results:
Hillock and club cell identity is established early and these cells extend into the proximal ducts of the adult prostate transition zone. Proximal fibroblasts surround the urethra and proximal ducts. BPH patients have increased club and hillock cells within glandular nodules compared to normal prostate tissue and proximal fibroblasts are increased in areas of peri-urethral fibrosis. Mouse scRNA-seq and IHC data confirmed the existence of cognate proximal fibroblasts and hillock epithelia, but club cells were not found.

Conclusions:
Our results show that club and hillock epithelia of the urethra and proximal ducts are established before prostate budding and are enriched in BPH glandular nodules, suggesting a potential cellular origin for new prostate growth. We also identify the proximal fibroblast of the human as the cellular source of collagen deposition in prostatic fibrosis, setting up a new phenotype to target in patients with LUTS. We created a cellular atlas of the mouse urethra and proximal prostate, which will allow for the generation of specialized mouse models to trace urethral and proximal fibroblast lineages. The cell types of the proximal ducts could become novel targets for the treatment of BPH/LUTS.
Sunday, November 10, 2019
11:40 – 11:50 a.m.
Travel Award Presentation #8:
Osteopontin Exacerbates the Inflammatory Environment in the Prostate
Petra Popovics, PhD
University of Wisconsin–Madison
Madison, WI

Background:
Chronic inflammatory processes are thought to contribute to the development of lower urinary tract symptoms (LUTS) in elderly men either via stimulating proliferation and triggering benign prostatic hyperplasia (BPH) or by triggering fibrosis in the periurethral region. Approximately 30% of patients with LUTS are resistant to existing therapies and identifying the inflammatory processes provoking tissue remodeling are essential to develop more efficient treatments. Our study aims to identify the role of osteopontin (OPN), a cytokine and fibrosis-associated protein elevated in experimental prostatitis, in inflammation and tissue remodeling in the prostate.

Methods:
OPN expression was detected by immunohistochemistry in prostates from patients without medical therapy or treated with α-blockers, 5-α reductase inhibitors or both and undergone surgery to relieve LUTS (sBPH, n=30). Incidental BPH (iBPH) is from the transitional zone of prostates from radical prostatectomy for low volume, low grade prostate cancer (n=8). Slides were captured with a Nuance multispectral camera and segmented and scored with inForm software. Immortalized stromal (BHPrS-1) and epithelial (NHPrE-1 and BHPrE-1) cell lines were used to determine the secretion of OPN in response to recombinant IL-1β and TGF-β1 by ELISA and genes activated by OPN were identified by qPCR.

Results:
OPN expression was detected in both glandular and stromal cells, although, it was not significantly elevated in sBPH patients compared to iBPH. However, OPN positivity was significantly higher in sBPH prostates when highly fibrotic samples with atrophic glands were eliminated from the iBPH group (p=0.0099). Multiple splice variants of OPN are expressed in the cell lines and its secretion is stimulated by TGF-β1 in NHPrE-1 and both IL-1β and TGF-β1 in BHPrS-1 cells. Most interestingly, we observed an increase in the expression of inflammatory genes in response to OPN including CXCL1, CXCL2, CXCL8, PTGS2 and IL6 in BHPrS-1, but this effect was not replicated in epithelial cells.

Conclusions:
Elevated levels of OPN exacerbates inflammation by stimulating stromal cytokine production. Pharmacological inhibition of OPN may have multiple beneficial effects to relieve LUTS by repressing the inflammatory environment in the prostate.
PS1-01
A next-generation functional genomics strategy to deconvolute compound genetic drivers and genotype-to-phenotype relationships in bladder cancer
2019 Eula and Donald S. Coffey Innovative Research Award Finalist
John K. Lee, M.D., Ph.D.; Assistant Member, Human Biology Division, Fred Hutchinson Cancer Research Center
Alicia Wong; Human Biology Division, Fred Hutchinson Cancer Research Center, Huiyun Sun; Human Biology Division, Fred Hutchinson Cancer Research Center, Sujata Jana, Ph.D.; Human Biology Division, Fred Hutchinson Cancer Research Center, Andrew C. Hsieh, M.D.; Assistant Member, Human Biology Division, Fred Hutchinson Cancer Research Center
https://drive.google.com/open?id=1igjg01Lsh5xk2pLyhX70w-HB4bMzT8.t

PS1-02
Myeloid-Derived Suppressor Cells Inhibit T Cell Activation in Prostate Cancer through Nitrating LCK
2019 Eula and Donald S. Coffey Innovative Research Award Finalist
Xin Lu, Ph.D., Boler Assistant Professor, University of Notre Dame; Indiana University
Shan Feng, Ph.D., Postdoctoral Fellow, Liang Cheng, M.D., Virgil Moon Professor of Pathology
https://drive.google.com/open?id=1TIKvi8kRftOij916p3bPh-41w-BVUSWgA

PS1-03
First Genetically Engineered Mouse Model of Penile Cancer and Its Application in Preclinical Immunotherapy
Xin Lu, Ph.D., Boler Assistant Professor, University of Notre Dame; Indiana University
Tianhe Huang, PhD, Postdoctoral Fellow, Pheroze Tamboli, MBBS, Professor, MD Anderson Cancer Center, Priya Rao, MD, Associate Professor, MD Anderson Cancer Center, Magaly Martinez Ferrer, PhD, Assistant Professor, University of Puerto Rico, Ronald A. DePinho, MD, Professor, MD Anderson Cancer Center, Curtis A. Pettaway, MD, Professor, MD Anderson Cancer Center
https://drive.google.com/open?id=1Cl5Mge2cXfg8lGH4LKyMgZMZHE2GkqwQq

PS1-04
A Novel Therapeutic Target For the Treatment of Lethal Prostate Cancer
2019 Eula and Donald S. Coffey Innovative Research Award Finalist
Salma Kaochar, PhD, Baylor College of Medicine
Additional Authors - Darlene Skapura, Matthew Robertson, Christel Davis, Erik Ehli, Kimal Rajapakshe, Cristian Coarfa, Bert O’Malley, Nicholas Mitsiades
https://drive.google.com/open?id=106zuyn5SuwMm44uvQGDmoxbJfdOspCy

PS1-05
PD-L1 is associated with the clinical features of human primary prostate tumors
2019 Travel Award Winner
Dongxia Ge, Tulane University, New Orleans, LA
https://drive.google.com/open?id=1uGNapp-CJyYgyTZ2hZEvQfjxDj5EkVpx

PS1-06
LSD1 activates PI3K/AKT signaling through regulating p85 expression in prostate cancer cells
Zifeng Wang, Center for Personalized Cancer Therapy, University of Massachusetts Boston
Prof. Shuai Gao, Dr. Dong Han, Wanting Han, Muqing Li, Prof. Changmeng Cai
https://drive.google.com/open?id=1oznHPNI-lHeA7xPg1kCSo_9d-5ywjkF
PS1-07
Interleukin-17 Upregulates MTA1 Expression to Promote Cancer Cell Migration and Invasion
2019 Travel Award Winner
Ahmed A. Moustafa, Postdoctoral Fellow, Department of Structural & Cellular Biology, Tulane University, New Orleans, LA
Na Guo, Department of Structural & Cellular Biology, Tulane University, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China, Ge Shen, Department of Structural & Cellular Biology, Tulane University, Ying Zhang, Department of Gynecology, Guangyuan First People's Hospital, Guangyuan, China, Dongxia Ge, Department of Structural & Cellular Biology, Tulane University, Zongbing You, Department of Structural & Cellular Biology, Department of Orthopedic Surgery, Tulane Cancer Center and Louisiana Cancer Research Consortium, Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane Center for Aging, Tulane University; Southeast Louisiana Veterans Health Care System, New Orleans
https://drive.google.com/open?id=1gONm-vC5C-phXqGaGgw8RXTT6mst6hQW

PS1-08
A novel model of prostate cancer suggests enzalutamide functions through the immune system to diminish castration resistant and metastatic growth
Steven Kregel, PhD, University of Michigan
Jae Eun Choi, Kristen Juckette, Brooke McCollum, Stephanie Simko, Parth Desai, Yuanuyuan Qiao PhD, Paul A. Volden PhD, and Arul M. Chinnaiyan MD, PhD
https://drive.google.com/open?id=1SnvYD4hFm0zwUGPqnNnffVtdfKvVsmjq

PS1-09
Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment
Steven Kregel, PhD, University of Michigan
Chao Wang, PhD, Xin Han, PhD, Lanbo Xiao, PhD, Ester Fernandez-Salas, PhD, Pushpinder Bawa, PhD, Brooke L. McCollum, Kari Wilder-Romans, BS, Xuhong Cao, MS, Corey Speers, MD/PhD, Shaomeng Wang, PhD, and Arul M. Chinnaiyan, MD, PhD
https://drive.google.com/open?id=1hzRJaQdw1offK01ZZvAJ5wjiWmmk8kQV

PS1-10
Trop2 as a Driver and Therapeutic Target for Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Phenotype
Tanya Stoyanova, PhD, Stanford University
En-Chi Hsu, Meghan A. Rice, Abel Bermudez, Fernando Jose Garcia Marques, Merve Aslan, Ali Ghoochani, Chiyuan Amy Zhang, Yun-Sheng Chen, Aimen Zlitni, Frezghab Habte, Sahil Kumar, Shiqin Liu, Kashyap Koul, Michelle Shen, Rosalie Nolley, Donna M. Peehl, Amina Zoubeidi, Sanjiv Sam Gambhir, Christian Kunder, Sharon Pitteri, James D. Brooks and Tanya Stoyanova
https://drive.google.com/open?id=1ldU0LI4SIRVnt8T1GVSoh5yLDvtuNin

PS1-11
3D Renal Organoids of Human Urinary Stem Cells for Nephrotoxicity Testing
Yuanyuan Zhang MD, PhD, Associate Professor, Wake Forest University, Institute for Regenerative Medicine
Haibin Guo MD PhD, Lei Dou MD PhD, Nan Deng MD PhD, Huifeng Ding MD PhD, Anthony Atala MD
https://drive.google.com/open?id=1oUCKQIvyBKyrqKq4A-ysxoRQSF3ALxN

PS1-12
Impaired Regeneration Potential of Urine-derived Stem Cells in Chronic Kidney Disease
Yuanyuan Zhang MD, PhD, Associate Professor, Wake Forest University, Institute for Regenerative Medicine
Geng Xiong MD PhD, Weiqing Tang MD PhD, Anthony J. Bleyer MD Nephrologist, Professor, Michael E. Bleyer Medical student, Antony Atala MD Urologist, Professor, Joseph A. Aloj MD, Endocrinologist Professor, Cristina M. Furdui PhD Professor
https://drive.google.com/open?id=1d3QJND0a3daUESYxoDQh6ikDxF9kTBW

PS1-13
Prostatic fibrosis is coupled to a mesenchymal IL4/IL13 autocrine loop
2019 Travel Award Winner
Mathilde L. Bonnemaison Ph.D., University of Massachusetts Boston
Mehrnaz Gharae-Kermani Ph.D., Jill A. Macoska Ph.D.
https://drive.google.com/open?id=1-aeOyFUbvlIC3eD10DzyOOhazP2HBmRe
PS1-14
Targeting P2X4 Purinergic Receptors in Aggressive Prostate Cancer
Janielle P. Maynard, PhD, Johns Hopkins University
Tamirat Ali, Angelo M. De Marzo, MD, PhD, Karen S. Sfanos, PhD
https://drive.google.com/open?id=1rnOUZgVBi-VGYuKKvbR5nfqFC4TTFSo

PS1-19
Lymphocyte Mediated Luminal Progenitor Cell Expansion in the Aging Prostate
Hector Ivan Navarro, Ph.D. Student, University of California, Los Angeles
Andrew Goldstein, Ph.D. -Principal Investigators
https://drive.google.com/open?id=1Jttqi2LYnYg7-HUGdW7vS2vc72yWHmT

PS1-15
Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate
Preston D. Crowell, University of California, Los Angeles
https://drive.google.com/open?id=1jzIoSNV43u_W1knG4ioD-Exs51oWjrD6

PS1-20
The Role of UDP-glucuronosyl transferase 2B28 in Prostate Cancer
2019 Travel Award Winner
Anindita Ravindran, BS - Graduate student, Baylor College of Medicine
Akash Kaushik, PhD - Postdoctoral associate, UT Southwestern Medical Center, Arun Sreekumar, PhD, Aj Professor, Baylor College of Medicine, Nagireddy Puturi, PhD, Aj Associate Professor, Baylor College of Medicine, Truong Dang, BS - Research technician, Baylor College of Medicine David Rowley, PhD - Professor, Baylor College of Medicine, Michael M Ittmann, PhD - Professor, Baylor College of Medicine, Uttam Rasaily, MS - Research technician, Baylor College of Medicine, Chandrashekar Reddy Ambati, MS - Research technician, Baylor College of Medicine, Nancy Weigel, PhD - Professor, Baylor College of Medicine, Balasubramanany Karanam, PhD, Aj Assistant Professor, Tuskegee University
https://drive.google.com/open?id=1Jttqi2LYnYg7-HUGdW7vS2vc72yWHmT

PS1-16
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy
Zongwei Wang, PhD, Harvard University
Tuo Deng, M.D., Xingbo Long, M.D., Xueming Lin, M.D., Shulin Wu, M.D., Hongbo Wang, Ph.D., Rongbin Ge, M.D., Zhenwei Zhang, Ph.D., Chin-Lee Wu, Ph.D. M.D., Mary-Ellen Taplin, M.D., Aria F. Olumi, M.D.
https://drive.google.com/open?id=19a90P8MMDFFmTqzwSlyab6f5DczVWjR

PS1-21
Nuclear factor I/B increases in prostate cancer to support androgen receptor activation
Jagpreet Singh Nanda, Postdoctoral fellow, Department of Urology, Case Western Reserve University
Wisam N. Awadallah, Research Assistant, Department of Urology, Case Western Reserve University, Sarah E. Kohrt, Graduate Student, Department of Pharmacology Case Western Reserve University, Petra Popovics, K12 Scholar, Department of Urology, University of Wisconsin School of Medicine and Public Health, Justin M. M. Cates, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center Janni Mirosevich, Department of Urology, Vanderbilt University Medical Center, Peter E. Clark, Department of Urology Levine Cancer Center/atrium Health, Giovanna A. Giannico, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center Magdalena M. Grabowska, Assistant Professor, Case Western Reserve University
https://drive.google.com/open?id=1wamU5x9u7wHleqDWDsyzSHWs44NFb

PS1-17
Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland
Zongwei Wang, PhD, Harvard University
Bichen Xue, MD, Shulin Wu, MD, Shahin Tabatabaei, MD, Chin-Lee Wu, MD, Zhiyong Cheng, MD, Li Xin, MD, Douglas Strand, MD, Aria F. Olumi, MD, Zongwei Wang, PhD
https://drive.google.com/open?id=1d9TpnRyCMgvy95oPY494QqeJS0m1-

PS1-18
Development of CRISPR human Skp2 knock-in in the prostate of mouse and the associated prostate organoids for testing Skp2 targeting agents
Liankun Song, postdoctoral scholar, University of California, Irvine
Xiaolin Zi, professor, Shan Xu, pathologist, Kia Arabzadehkaffash, undergraduate student, Ali Fazelpour, undergraduate student, Dongjun Fu, postdoc, Matthew Tippin
https://drive.google.com/open?id=1gzzruhsKuWpwfOsWPVzWilM4i4o0nffH
PS1-22
Macrophase recruitment, activation and neural cross-talk are associated with development and maintenance of chronic pelvic pain
Dr. Zhiqiang Liu, Department of Urology, Feinberg School of Medicine, Northwestern University
Dr. Stephen F. Murphy, Department of Urology, Feinberg School of Medicine, Northwestern University, Larry Wong, Department of Urology, Feinberg School of Medicine, Northwestern University, Dr. Anthony J. Schaeffer, Department of Urology, Feinberg School of Medicine, Northwestern University, Dr. Praveen Thumbikat, Department of Urology, Feinberg School of Medicine, Northwestern University
https://drive.google.com/open?id=1-q6p_rzYgK7AWr4MCKDHQzbyaF51

PS1-23
Epigenetic modifications drive autoimmunity in CPPS
Stephen Murphy, Ph.D., Department of Urology, Feinberg School of Medicine, Northwestern University
Dr. Anthony J. Schaeffer, MD, Dr. Praveen Thumbikat, DVM, PhD
https://drive.google.com/open?id=1HQ42L0kTEdqSE5sqUSpMgtwLujFgpA2P

PS1-24
Urinary Metabolites for the Risk Stratification of Prostate Cancer
2019 Travel Award Winner
Qin Gao Ph.D., Postdoctoral Researcher, University of Texas at El Paso
Xiaogang Su Ph.D., Professor, University of Texas at El Paso, Heinric Williams, M.D., FACS, Physician, Geisinger Medical Center, Michael Hani Annabi, M.D., Physician, The Clinic Internal Medicine, Wen-Yee Lee Ph.D., Associate Professor, University of Texas at El Paso
https://drive.google.com/open?id=1TeSctk-LitCC0IYl5rCho7s-1IsMt7F8

PS1-25
Application of Urinary Volatile Organic Compounds for the Diagnosis of Renal Cancer
Wen-Yee Lee Ph.D., Associate Professor, University of Texas at El Paso
Qin Gao Ph.D., Postdoctoral Researcher, University of Texas at El Paso, Xiaogang Su Ph.D., Professor, University of Texas at El Paso, Heinric Williams M.D., FACS, Physician, Geisinger Medical Center
https://drive.google.com/open?id=19YoRnxMv7xH_jhwLyu2bjpVSSfpuQFPq0

PS1-26
MAP3K11 drives in vitro enzalutamide resistance in castration-resistant prostate cancer
2019 Travel Award Winner
Sarah Kohrt, Case Western Reserve University
Wisam Awadallah, Magdalena Grabowska, PhD
https://drive.google.com/open?id=1N-nwQCKfkTjN07tCgf6pQfrt9jA

PS1-27
Therapeutic potential of targeting macrophages in castration resistant prostate cancer
Asmaa El-Kenawi, PhD, Moffitt Cancer Center
Additional Authors - William Dominguez Viqueira, PhD Lee Noel Brian Ruffell, PhD
https://drive.google.com/open?id=18vTiZi6tDCNaA9xwbnHqw8pp-7d8E

PS1-28
LSD1-mediated demethylation of FOXA1 regulates AR cistrome in Prostate Cancer
Shuai Gao Ph.D., Research Assistant Professor, University of Massachusetts-Boston
Sujun Chen, Dong Han, Zifeng Wang, Muqing Li, Wanting Han, Anna Besschetnova, Feng Zhou, David Barrett, My Phu Luong, Jude Owiredu, Yi Liang, Musaddeque Ahmed, Jessica Petricca, Jill A. Macoska, Eva Corey, Sen Chen, Steven P. Balk, Housheng Hansen He, and Changmeng Cai
https://drive.google.com/open?id=1LxpkKGEiTg8lm5skwjUtC5UXBd5OehTQW

PS1-29
CCL25 neutralization enhances efficacy of Doxetaxel in preclinical prostate cancer model
Hina Mir, PhD., Morehouse School of Medicine
Neeraj Kapur, PhD., Sejong Bae, PhD., Guru Sonpavde, MD, James W. Lillard, Jr., PhD., MBA and Shailesh Singh, PhD.
https://drive.google.com/open?id=1R8x19geDZLeKCDMttXfy9wl.qLruD6B9
PS1-30  
Differential role for SIRT1 in prostate cancer development and progression  
2019 Travel Award Winner
Shih-Bo Huang, MS, University of Texas Health Science Center at San Antonio  
Dinesh Thapa, PhD, Amanda R Muñoz, PhD, Suleman S. Hussain, PhD, Xiaoyu Yang, MS, Roble G Bedolla, MD, Zhao Lai, PhD, Yidong Chen, PhD, Paul Rivas, Claire Shudde, Pawel Osmulski, PhD, Maria Gaczynska, PhD, Robert L Reddick, MD, Hiroshi Miyamoto, MD, PhD, Rita Ghosh, PhD, Addanki Pratap Kumar, PhD  
https://drive.google.com/open?id=1vJlpoPfrAyfuE-vmrphdKglIAe6Vxpr

PS1-31  
Loss of Androgen Receptor in Prostate Cancer Stroma Inhibits Luminal Epithelial Differentiation  
Shekha Tahsin, Cancer Biology Graduate program, University of Arizona  
Linan Jiang, Research Assistant Professor, Aerospace and Mechanical Engineering; Yitshak Zohar, Professor, Aerospace and Mechanical Engineering, Cindy K. Miranti, Professor, Cellular and Molecular Medicine  
https://drive.google.com/open?id=1XFVUWhS8p8AKiyMwl8mLzXbdF2YPN5

PS1-32  
Decreased glucose bioavailability and elevated aspartate metabolism in prostate cancer cells undergoing epithelial-mesenchymal transition  
Yule Chen, PhD, MD, Department of Urology, The First Hospital of Xi'an Jiaotong University  
Ke Wang PhD, Lei Li, PhD, MD  
https://drive.google.com/open?id=1PUEjzX1gaSAzdITu2XO3tiwjBjiZs_P

PS1-33  
Exogenous testosterone and estradiol prolong prostate smooth muscle relaxation via downregulation of MYPT2: a novel utility for genetically encoded calcium receptors  
Anne E Turco, University of Wisconsin-Madison  
Steven R Oakes, Allison Rodgers, Celeste Underriner, Mark Cadena, Richard E Peterson, Laura Hernandez, Tim Hacker, Nathan Tykocki, Chad M Vezina  
https://drive.google.com/open?id=1EkszMjXgKwghV2jJQelkJA4AZ6nBuTP

PS1-34  
Temporal Analysis of Signaling Events Leading to Bladder Remodeling after Spinal Cord Injury  
Ali Hashemi, PhD, Harvard Medical School/Boston Childrens Hospital  
Bryan S. Sack, MD, Mary Piper, PhD, Justin F. Cotellezza, PhD, Claire Doyle, PhD, Mehrnaz Gharaei-Kermani, PhD, Amy Avery, PhD, Vivian Cristofaro, PhD, Maryrose P. Sullivan, PhD, Fiona C. Burkhard, MD, Katarina MonasterioKajka, PhD, Jill A. Macoska, PhD, Rosalyn M. Adam, PhD  
https://drive.google.com/open?id=1Cd80Gux_sIeFzLzzQvgNeOwX0VSwm6O

PS1-35  
Development of a Whole-Urine, Multiplexed, Next Generation RNA-Sequencing Assay for the Early Detection of Aggressive Prostate Cancer  
Dr. Simpa Salami, MD, MPH, University of Michigan  
Andi K. Cani, Kevin Hu, Javed Siddiqui, Yingye Zheng, PhD Sumin Han, PhD, Srinivas Nallandhilligal, Trinh Pham, Chia-Jen Liu, Daniel H. Hovelson, PhD, Lanbo Xiao, PhD, Heng Zheng, Jeffrey J. Tosoiain, MD, Ganesh S. Palapattu, MD, FACS, Todd M. Morgan, MD, Aaron Udager, MD, PhD, Arul M. Chinnainay, MD, PhD, John T. Wei, MD, Scott A. Tomlins.  
https://drive.google.com/open?id=1469scbY4lRO0UwSGzjVPREpTvKHrr

PS1-36  
Targeting steroid sulfatase with novel inhibitors suppresses CRPC tumor growth and improves response to enzalutamide  
2019 Travel Award Winner
Cameron M. Armstrong, PhD, UC Davis  
Chengfei Liu, MD, PhD, Liangren Liu, MD, Joy C. Yang, PhD, Wei Lou, MD, Christopher P. Evans, MD, Pui-Kai Li, PhD, Allen C. Gao, MD  
https://drive.google.com/open?id=1v2P8pcjWcvU2Xnc5eFlFN44T73Sc_8

PS1-37  
Role of mast cells in an uropathogenic Escherichia coli induced model of lower urinary tract symptoms associated with benign prostatic hyperplasia  
Goutham Pattabiraman, Ph.D., Northwestern University  
Daniel J. Mazur, Ph.D.Joseph D. Done, B.S.Ashlee Bell-Cohn, B.S.Anthony J Schaeffer, M.D.Praeven Thumikia, Ph.D., D.V.M.  
https://drive.google.com/open?id=1j8a6ishwXb6bc4u7xIAAaPDVIAAlk4eh
PS1-38
A Novel Syngeneic Mouse Model of Prostate Cancer Bone Metastasis: Mechanisms of Chemotaxis and Bone Colonization
Srinivas Nandana, Assistant Professor, Dept. of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock
Murari Gururaj, Manisha Tripathi, Chia-Yi Chu, Haiyen E. Zhai, Stephen L. Shiao, Leland W.K. Chung
https://drive.google.com/open?id=1w-NT0UeH3UfP5z_NO1-bj3aCmoebkiUJ

PS1-39
A genetically defined tumor model characterizes small cell carcinoma of the bladder
2019 Travel Award Winner
Liang Wang, Ph.D., University of California, Los Angeles
Bryan A. Smith, Ph.D.; Nikolaos G. Balanis, Ph.D.; Brandon L. Tsai, B.S.; Kim Nguyen, B.S.; Michael W. Cheng; Matthew B. Obusan, B.S.; Favour N. Esedebe, B.S.; Saahil J. Patel, B.S.; Hanwei Zhang, Ph.D.; Peter M. Clark, Ph.D.; Anthony E. Sisk, DO; Jonathan W. Said, MD; Jiaoti Huang, MD, Ph.D.; Thomas G. Graber, Ph.D.; Owen N. Witte, MD; Arnold I. Chin, MD, Ph.D.; Jung Wook Park
https://drive.google.com/open?id=11acBMmjGFyDYokxzmFfa1QilM3hKC475

PS1-40
Identification of a Novel PRC2 Complex as a Therapeutic Target in Castration Resistant Prostate Cancer
2019 Travel Award Winner
Ka-Wing Fong PhD, Northwestern University
Jonathan C. Zhao, PhD, Xiaodong Lu, PhD, Jung Kim, PhD, Andrea Piunti, PhD, Rakshitah Jagadish, MS, Jindan Yu, MD PhD
https://drive.google.com/open?id=1tqx8mH-SOxxuj-88_5pdgs-SYFBp6Qaf

PS1-41
Fibroblasts accumulate and produce collagen in dogs prone to prostate related urinary dysfunction
Hannah Ruetten, University of Wisconsin- Madison
Marlyse Wehber*1,2, Clara Cole*1,2, Mark Cadena2, Kyle A. Wegner2,3, Michael F. Romero4, Michael W. Wood5, Sara A. Colapy6, Dale E. Bjorling6, and Chad M. Vezina1,2,3*authors contributed equally to this project, Department of Comparative Biomedical Sciences, School of Veterinary Medicine, University of Wisconsin- Madison, George M. O'Brien Benign Urology Center, University of Wisconsin- Madison, Molecular and Environmental Toxicology Center, School of Medicine and Public Health, University of Wisconsin- Madison, Madison, Molecular and Environmental Toxicology Center, School of Medicine and Public Health, University of Wisconsin- Madison, Physiology and Biomedical Engineering and Nephrology and Hypertension, George M. O'Brien Urology Research Center, Mayo Clinic College of Medicine and Science, Rochester, MN, Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin- Madison, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin- Madison
https://drive.google.com/open?id=1FOMKEFijEDZL3KRby_70hAFXh7wGLo4B

PS1-42
A Retrospective Medical Record Review of Benign Prostatic Hyperplasia in a Well-Defined Population of Client-Owned Dogs: Clinical Presentation, Prevalence of Concurrent Bacterial Infection, and Response to Treatment
Hannah Ruetten, University of Wisconsin- Madison
Clara Cole*1,2, Marlyse Wehber*1,2, Simran Sandhu1,2, Steven R. Oakes1,2,3, Kenneth Waller III4, Chad M. Vezina1,2,5, and Katrina Viviano6*authors contributed equally to this project. 1Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI2, University of Wisconsin-Madison/UMASS Boston George M. O’Brien Center for Benign Urologic Research, Madison, WI and Boston, MA, Department of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI4Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI5, Molecular and Environmental Toxicology Center, University of Wisconsin-Madison, Madison, WI6, Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison
https://drive.google.com/open?id=1A6rdhqLLxG216szfG0_0iwpu90tfijY6
**PS1-43**

Estrogen mediated racial disparity in men with benign prostatic hyperplasia

2019 Travel Award Winner

**Teresa T Liu, PhD, University of Wisconsin – Madison**

Emily A. Ricke, MA, Douglas Strand, PhD, Rajiv Dhir, M.D., MBA, William A. Ricke, Ph.D.

[https://drive.google.com/open?id=1KBYLoyuuZsRdNsp1VdRnD6kCdFb7F8ut](https://drive.google.com/open?id=1KBYLoyuuZsRdNsp1VdRnD6kCdFb7F8ut)

**PS1-44**

Inhibition of EZH2 enhances the antitumor efficacy of metformin in prostate cancer

Yifan Kong

[https://drive.google.com/open?id=1nK1anU_Uhc0gNC58XY78njmWX1c8dmg](https://drive.google.com/open?id=1nK1anU_Uhc0gNC58XY78njmWX1c8dmg)

**PS1-45**

Screening of histone post-translational modifications in castration resistant prostate cancer reveals CHD1 gene deficiency engenders a distinct epigenetic profile

Joseph Gawdzik PhD, University of Wisconsin

Additional Authors - Eric Armstrong MS, Bing Yang PhD, Rehann Machhi, John Denu PhD, David Jarrard MD

[https://drive.google.com/open?id=1QLXdaAUCvembkeSsdv91Er7VifuyaNe6](https://drive.google.com/open?id=1QLXdaAUCvembkeSsdv91Er7VifuyaNe6)

**PS1-46**

Methoxychalcone derivative as a potent inhibitor of aggressive prostate cancer through glycolytic targeting

Meghan A. Rice, PhD, Stanford University

Vineet Kumar, PhD, Dhanir Tailor, PhD, Fernando Jose Garcia Marquez, PhD, Abel Bermudez, Zintis R. Inde Vijaya Kanchustambham, PhD, Ali Ghoochani, PhD, Rosalie Nolley, Mallesh Pandrala, PhD, Angel Resendez, PhD, Merve Aslan, MS, Arushi Agarwal, Mark Buckley, Shiqiu Liu, MD PhD, En-Chi Hsu, PhD, Catherine Going, PhD, Donna Peehl, PhD, Scott J. Dixon, PhD, Richard Zare, PhD, James D. Brooks, MD, Sharon Pitteri, PhD, Sanjay Malhotra, PhD, Tanya Stoyanova, PhD

[https://drive.google.com/open?id=1jIYsI9X5bkzna5LkktZFnUMKEKlNTPP](https://drive.google.com/open?id=1jIYsI9X5bkzna5LkktZFnUMKEKlNTPP)

**PS1-47**

Development of Lidocaine-Eluting Catheter Catheter-Induced Bladder Pain

Eun Bi Jang, Department of Urology, Hanyang University College of Medicine, Seoul, Korea

Ja Young Lee, Young Eun Yoon, Sung Yul Park, Hong Sang Moon, Department of Urology, Hanyang University College of Medicine, Seoul, Korea

[https://drive.google.com/open?id=1GhJIFu03ULPN_xz_wbG02yC-w8Xpc3O](https://drive.google.com/open?id=1GhJIFu03ULPN_xz_wbG02yC-w8Xpc3O)

**PS1-48**

The impact of ginsenoside and everolimus use on renal cell carcinoma

**Ji-Young Lee, Department of Urology, Hanyang University College of Medicine, Seoul, Korea**

Dae Keun Kim, Sung Yul Park, Young Eun Yoon, Department of Urology, Hanyang University College of Medicine, Seoul, Korea

[https://drive.google.com/open?id=1NeMX67mFlf2RTu0aIV-sBDJG5VT](https://drive.google.com/open?id=1NeMX67mFlf2RTu0aIV-sBDJG5VT)

**PS1-49**

The Anticancer Effect of Ginsenoside Rg3 and Rh2 in Renal Cell Carcinoma

**Ji-Young Lee, Department of Urology, Hanyang University College of Medicine, Seoul, Korea**

Dae Keun Kim, Sung Yul Park, Young Eun Yoon, Department of Urology, Hanyang University College of Medicine, Seoul, Korea

[https://drive.google.com/open?id=1oehKque5q-KKd_lgud-dlbhkGdDwH](https://drive.google.com/open?id=1oehKque5q-KKd_lgud-dlbhkGdDwH)

**PS1-50**

A preclinical study of the combination treatment of high-dose testosterone and CDK4/6 inhibitors in CRPC

**2019 Travel Award Winner**

**Wanting Han, University of Massachusetts Boston**

Anthia A Toure, Dong Han, Postdoctoral Fellow, Shuai Gao, Research Assistant, Professor Changmeng Cai, Assistant Professor

[https://drive.google.com/open?id=1B9xxDRHxqdbn8s76QJ94vZls86-XaH](https://drive.google.com/open?id=1B9xxDRHxqdbn8s76QJ94vZls86-XaH)

**PS1-51**

Prostate Neuroendocrine Cell Serotonin Aids to Prevent Microbial Infection

**Mark Cadena, University of Wisconsin - Madison**

Jonathan Zhu - UW-Madison Summer Program in Undergraduate Urology Research, Madison, WI; PeiQing Wang - Cardiovascular Research Center, Madison, WI; Celeste Underriner - UW-Madison Molecular and Cellular Pharmacology Graduate Program, Madison, WI; Laura Hernandez - UW-Madison Dept. of Dairy Science, Madison, WI; Nathan Tykocki - UW-Madison Dept. of Pharmacology, Burlington, VT; Tian Shen - University of Columbia Dept. of Medicine, New York City, NY; Jonathan Barasch - University of Columbia Dept. of Medicine, New York City, NY; Michael Romero - Mayo Clinic College of Medicine & Science, Dept. of Physiology & Biomedical Engineering and Nephrology & Hypertension, Rochester, MN; Chad Vezina - UW-Madison Dept. Comparative Biosciences, Madison, WI

[https://drive.google.com/open?id=189rDy9dSc-7JloxF-JEbkeHRGKxVYU](https://drive.google.com/open?id=189rDy9dSc-7JloxF-JEbkeHRGKxVYU)

**PS1-52**

Prostate Neuroendocrine Cell Serotonin Aids to Prevent Microbial Infection

**Mark Cadena, University of Wisconsin - Madison**

Jonathan Zhu - UW-Madison Summer Program in Undergraduate Urology Research, Madison, WI; PeiQing Wang - Cardiovascular Research Center, Madison, WI; Celeste Underriner - UW-Madison Molecular and Cellular Pharmacology Graduate Program, Madison, WI; Laura Hernandez - UW-Madison Dept. of Dairy Science, Madison, WI; Nathan Tykocki - UW-Madison Dept. of Pharmacology, Burlington, VT; Tian Shen - University of Columbia Dept. of Medicine, New York City, NY; Jonathan Barasch - University of Columbia Dept. of Medicine, New York City, NY; Michael Romero - Mayo Clinic College of Medicine & Science, Dept. of Physiology & Biomedical Engineering and Nephrology & Hypertension, Rochester, MN; Chad Vezina - UW-Madison Dept. Comparative Biosciences, Madison, WI

[https://drive.google.com/open?id=189rDy9dSc-7JloxF-JEbkeHRGKxVYU](https://drive.google.com/open?id=189rDy9dSc-7JloxF-JEbkeHRGKxVYU)
**PS1-52**

Sanguinarine (SNG) is a novel dual-inhibitor of Lysine-specific demethylase 1A (LSD1) and androgen receptor (AR) against castration-resistant prostate cancer

2019 Travel Award Winner

Victor Pham, University of California, Irvine

Victor Pham, Vinh X Le, Dongjun Fu, Thanh NH Le, Marvin Miller, Matthew Tippin, Liankun Song, Xiaolin Zi

[https://drive.google.com/open?id=1s7C1S4vef0YBn3f5qsNgKI ttXgnabjTQ](https://drive.google.com/open?id=1s7C1S4vef0YBn3f5qsNgKI ttXgnabjTQ)

---

**PS1-53**

Characterization of a novel androgen receptor variant, VBI-1, in bladder cancer

Kimberley D. Katleba, PhD, University of California, Davis

Alan P. Lombard, PhD, Chris A. Lucas, Kristine S. Nishida, Han Bit Baek, Paramita Ghosh, PhD, Maria Mudryj, PhD

[https://drive.google.com/open?id=1msQzQZ7i20Yr_LoBCH4LE zlP1N87yENq](https://drive.google.com/open?id=1msQzQZ7i20Yr_LoBCH4LE zlP1N87yENq)

---

**PS1-54**

Molecular determinants for enzalutamide-induced oncogenic transcription in prostate cancer

Fuwen Yuan, Duke University

William Hankey (postdoctoral fellow), Dayong Wu (research associate), Hongyang Wang (senior research scientist), Jason Somarelli (medical instructor), Andrew J. Armstrong (professor), Jiaoti Huang (professor), Zhong Chen (assistant professor), Qianben Wang (professor)

[https://drive.google.com/open?id=1cXIsqyRiVdZQpOBNhVQ 8kRlHBrq8gzH](https://drive.google.com/open?id=1cXIsqyRiVdZQpOBNhVQ 8kRlHBrq8gzH)

---

**PS1-55**

Big-data analysis reveals a role of opiorphin encoding genes in prostate cancer and possible genetic mechanisms modulating tumor growth and androgen-sensitivity

Dr. Kelvin P. Davies, Albert Einstein College of Medicine

Dr. Amarnath Mukherjee, Mr. Augene Park

[https://drive.google.com/open?id=1VVzz5Dx9UoMQ8PDIAEdX hM3inRbZe3qXx](https://drive.google.com/open?id=1VVzz5Dx9UoMQ8PDIAEdX hM3inRbZe3qXx)

---

**PS1-56**

Hit-to-Lead Optimization of a First-in-Class FKBP52 inhibitor for the Treatment of Castration Resistant Prostate Cancer

Ashley Nichole Payan - PhD Student, University of Texas at El Paso

Naihsuan C. Guy, Marc B. Cox – PI

[https://drive.google.com/open?id=14yjQP8-RAUIlcLwwPSbgz4_a_vKbgvT](https://drive.google.com/open?id=14yjQP8-RAUIlcLwwPSbgz4_a_vKbgvT)

---

**PS1-57**

Facilitating Biological and Clinical Discoveries Using The Prostate Cancer Transcriptome Atlas

Sungyong You PhD, Assistant Professor in Surgery and Biomedical Sciences at Cedars-Sinai Medical Center

Minhyung Kim Ph.D., a Post-doctoral fellow in Surgery and Biomedical Sciences at Cedars-Sinai Medical Center, Junhee Yoon M.S., a Software engineer in Surgery and Biomedical Sciences at Cedars-Sinai Medical Center, Jayyoung Kim Ph.D., Associate Professor in Surgery and Biomedical Sciences at Cedars-Sinai Medical Center, Michael R Freeman Ph.D., Professor in Surgery and Biomedical Sciences at Cedars-Sinai Medical Center

[https://drive.google.com/open?id=1TMy6PR_HtoHz6VM6msT wfr-N5WFXb-](https://drive.google.com/open?id=1TMy6PR_HtoHz6VM6msT wfr-N5WFXb-)

---

**PS1-58**

Upregulation of Androgen Receptor Splice Variants, ¿Is an Inevitable Response to Androgen-Directed Therapies?

Tianfang Ma, Graduate Student, Tulane University - Biomedical Sciences Graduate Program

Shanshan Bai, Graduate student, Jinlin University - College of Life Science; Nathan Ungerleider, Postdoc Fellow, Tulane University - Dpt. Pathology; Yang Zhan, Associate Professor, Jinlin University - College of Life Science; Yan Dong, Professor, Tulane University - Dpt. Structural and Cellular Biology; Erik Flemington, Professor, Tulane University - Dpt. Pathology

[https://drive.google.com/open?id=1cjsCmTM47A7Dn_cUkIl5k8 trU4wWYYY8](https://drive.google.com/open?id=1cjsCmTM47A7Dn_cUkIl5k8 trU4wWYYY8)

---

**PS1-59**

Developing New Bone Metastasis Models through Tissue-Engineering and Microfluidics

Bethany Kerr, Ph.D., Assistant Professor, Wake Forest School of Medicine

Koran Harris, Graduate Student, Chirayu Patel, Graduate Student, Alexander Jinnah, Graduate Student, Ellen Quillen, Assistant Professor, Arvind Chandrasekaran, Assistant Professor

[https://drive.google.com/open?id=1AW8k9w_3D36Oawvk05Cbn rN_2f4N-3qf](https://drive.google.com/open?id=1AW8k9w_3D36Oawvk05Cbn rN_2f4N-3qf)
PS1-60
MicroRNAs in metastatic lymph node as diagnostic tool for prostate cancer
Jenie Marian Cruz Burgos, PhD Student, Universidad Nacional Autonoma de Mexico
Dr. Jorge Gustavo Morales Montor PhD Student, Sergio Alberto Cortez Ramirez PhD student, Carlos David Cruz Hernandez Medical Student. Samantha Ivone Trujillo Bornios MSc, Alberto Losada Garcia Pl. Mauricio Rodriguez Dorantes
https://drive.google.com/open?id=1NpJr_82h7f05zf1v8IedFb2cx0DZd-z

PS1-61
WLS Promotes Cellular Viability and Resistance to Enzalutamide in CRPC
Alan P Lombard, PhD, University of California, Davis Chengfei Liu, MD PhD, Cameron M Armstrong, PhD, Leandro S D’Abronzo, PhD, Wei Lou, MD, Christopher P Evans, MD, Allen C Gao, MD PhD
https://drive.google.com/open?id=1WzM7hLTaDYF-eyj_Jldzqc_BtDjwEfv

PS1-62
Metabolic Re-wiring in African-American Prostate Cancer: A Role for Adenosine-Inosine Axis in Tumor Progression
Christy Charles, Graduate Student, Baylor College of Medicine
Jie Golkhe, Baylor College of Medicine, Stacy Lloyd, Baylor College of Medicine, Uttam Rasaily, Baylor College of Medicine, James Henderson, University of Michigan, Balasubramaniam Karnam, Tuskegee University, Nora Navone, MD Anderson Cancer Center, Rick Kittles, City of Hope Comprehensive Cancer Center, Stefan Amb, National Cancer Institute, George Michaelidis, University of Florida, Nagireddy Putluri, Baylor College of Medicine, Arun Sreekumar, Baylor College of Medicine
https://drive.google.com/open?id=1bxWJJKZBdyHXNg_hE7jU0ehpJNabcCG

PS1-63
Plk1 inhibition enhances the efficacy of BET epigenetic reader blockade in castration-resistant prostate cancer
Fengyi Mao, Graduate student, University of Kentucky
Fengyi Mao, Dr. Jie Li, Ruixin Wang, Yifan Kong and Dr. Xiaoqi Liu
https://drive.google.com/open?id=1yplcw-nw85Vejhq4PFNfipH6PE3zJxQ

PS1-64
Urinary Bacteria Meet Heme Metabolism at the Bladder Surface
Jonathan Barasch MD PhD, Columbia University
Tian Shen PhD; Katherine Xu PhD; Yuanji Li BA; Ali Gharavi MD; Anne Catrine Uhleman MD PhD; Cathy Mendelsohn PhD
https://drive.google.com/open?id=1K5wq_Qv2Sptns0bLyy1hJ6oGv4SRfF3

PS1-65
Characterization of Inflammatory Cells in Human Benign Prostatic Hyperplasia
Renee E. Vickman, PhD, NorthShore University Health System
Gregory M. Cresswell,PhD, Nadia A. Lanman, PhD, Meaghan M. Broman, DVM, Omar E. Franco, MD, PhD, Brian T. Helfand, MD, PhD, Alexander Glaser, MD, Timothy L. Ratliff, PhD, and Simon W. Hayward, PhD
https://drive.google.com/open?id=1rpoMRCzbmF-PVFolocYN4zU4nafbR72u

PS1-66
p300 inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
Dr. Jinghui Liu, University of Kentucky
Dr. Daheng He, Dr. Lijun Cheng, Dr. Karrie Jones, Dr. Dana Napier, Dr. Eun Y. Lee, Dr. Chi Wang and Dr. Xiaoqi Liu
https://drive.google.com/open?id=1XVC8q22-rAwxm5aZzeYdllB1QGrLxCqT

PS1-67
Cranberry’s Role in the Prevention of Urinary Tract Infections
Jenaye Wanke, PA-S, University of Texas Medical Branch Stacey Lopez, PA-S, Lailee Madani, PA-S, Rosalyn Velasquez, PA-S
https://drive.google.com/open?id=1KDC5uYCrMj77dr4slt1q7ox8aY8cG2c

PS1-68
Keratinocyte Growth Factor Blocks Radiation-Induced Cystitis
Rebecca A Georgiadias, University of Pittsburgh
Sridhar T Narla PhD, Caitlin M Schaef er MPH, Daniel Bushnell Carlton M Bates MD
https://drive.google.com/open?id=11UnFc8KDQ7aSQCq67FTHl9n5x_blAlp
PS1-69
The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells
Martina Gruber, MSc, Medical University of Innsbruck
Florian Handle, PhD, Zoran Culig, MD
https://drive.google.com/open?id=1jSTgaWS4iPDqsEH8VMrvcfMQyqgYMqEM

PS1-70
FGF-P: A potential mitigator of radiation-induced GI damage
Lori Rice, Ph.D., University of Florida
Steven Swarts, Ph.D., Paul Okunieff, M.D., Dietmar W. Siemann, Ph.D., Bingrong Zhang, DVM, Ph.D., Zhenhuan Zhang, Ph.D., Ashantea Hope, Sharon Lepler
https://drive.google.com/open?id=1FY_pO83ChJ_u6bZOw5FwSxHUdMRXYtS9

PS1-71
PRMT5 cooperates with pICln to function as a master epigenetic activator of DNA double-strand break repair genes
Jake L. Owens, Purdue University
Elena Beketova, Dr. Sheng Liu, Samantha L. Tinsley, Andrew M. Asbery, Xuehong Deng, Dr. Jiaoti Huang, Dr. Chenglong Li, Dr. Jun Wan, Dr. Chang-Deng Hu
https://drive.google.com/open?id=1DplKz9VqzNnt11k1uRPsNuGitThrTnc

PS1-72
KGF reduces injury and accelerates recovery of bladder urothelium after cyclophosphamide
Srithar T. Narla, PhD, University of Pittsburgh
Daniel S. Bushnell, Caitlin M. Schaefier, MPH, Medhi Nouraie, MD, PhD, Carlton M. Bates, MD
https://drive.google.com/open?id=1qCtguQZ49-vd1PjtDefZF-WxCvtdG00Z

PS1-73
Prostate cancer cell phenotypes are stable following PDE5 inhibition in the clinical range but antagonized by supra-physiological concentrations.
William Hankey, Ph.D., Duke University
Benjamin Sunkel, Ph.D., Zhong Chen, Ph.D., Xiaolong Cheng, Ph.D., Jennifer M. Thomas-Ahner, Ph.D., Jeff Groth, B.A., Yue Zhao, M.D., Victor X. Jin, Ph.D., Steven K. Clinton, M.D., Ph.D., Jiaoti Huang, M.D., Ph.D., Qianben Wang, Ph.D.
https://drive.google.com/open?id=1uN1ePGj6PfCjpsjIFG41kgoz-0qV

PS1-74
Overall Survival in Patients with Metastatic Prostate Cancer: Role of Statins and PSA Nadir after Androgen Deprivation Therapy
Salma Siddiqui M.D.
Blythe P. Durbin Johnson, Stanley Yap M.D., Ralph W. deVere White M.D., Paramita Ghosh PhD.
https://drive.google.com/open?id=1fkv_n1i2KJ-W0glakgkAM3Gd7EI.ai

PS1-75
CRISPRi screen of risk-associated cis-regulatory elements reveals 3D genome dependent causal mechanisms in prostate cancer
Housheng Hansen He - Senior Scientist/Associate Professor, Princess Margaret Cancer Centre
Musaddeque Ahmed - Postdoctoral Fellow, Fraser Soares - Postdoctoral Fellow, Jihan Xia - Graduate Student, Gonghong Wei - Full professor
https://drive.google.com/open?id=1rE1UTBTkXVZY1EWtSHeCn9pySqVRV

PS1-76
GATA-2 and Twist-1 as Targets of CREB-1 in Prostate Cancer Development
Kasturi Banerjee, Assistant Scientific Investigator, University of Arizona Cancer Center
McLane Watson, Student, Penny Berger, Technician, Cindy Miranti, Professor/Principal Investigator
https://drive.google.com/open?id=1kIdHAIQy4dBK-dglwO6pu4RiZnBSe9FTF

PS1-77
The critical role of Interleukin-8 chemokine axis in the development of benign prostatic hyperplasia (BPH)
Diandra K. Smith, MPH, Research Associate, Augusta University
Natasha Venugopal, BS Medical Student (MS2), Martha K. Terris, MD, Chief of Urology, Professor Vinata B. Lokeswar, PhD, Department Chair Professor Bal L. Lokeswar, PhD
https://drive.google.com/open?id=1nhAhbAPK8N74Zx87G-7zapN6VE-wJKN

PS1-78
Defining the Androgen Receptor-dependent transcriptome in bladder tumor cells
Maria Mudryj, University of California, Davis
Kimberly D. Kettleba, Ph.D., Christopher A. Lucas, Clifford Tepper, Ph.D., Paramita Ghosh, Ph.D., Maria Mudryj, Ph.D.
https://drive.google.com/open?id=18B2ZC2uWExK1tZGDBLsWS9DmNzp3IVLiT
PS1-79
Snail Promotes Neurite Outgrowth in Prostate Cancer Cells
Gabrielle Edwards, Clark Atlanta University
Janae Sweeney, Veronica Henderson, Valerie Odero-Marah
https://drive.google.com/open?id=1Vtxo8aUyj5HDRsVilk7hSo62NdaxCe8J

PS1-80
Inducible prostate luminal epithelial cell-specific deletion of Cdh1 induces murine prostatic hyperplasia and inflammation and bladder overactivity
Laura E. Pascal, PhD, University of Pittsburgh School of Medicine
Shinsuke Mizoguchi, MD; Marcelo Carratino, PhD; Rajiv Dhir, MD; Wei Chen, PhD; Ke Wang, BS; Daniel Metzger, PhD; Pierre Chambon, PhD; and Zhou Wang, PhD
https://drive.google.com/open?id=1mvnjsmESMACAPQePYPojXWjh4J1jPMe

PS1-81
Foxa1 expression is required for maintenance of superficial umbrella cells in the urothelium
Lauren Shuman, MS, Penn State University
Jenna Buckwalter, Thomas Wildermuth, Klaus Kaestner, Cathy Mendelsohn, David DeGraff
https://drive.google.com/open?id=1uyrGR1axvbq3lCpYKNC8bX36TIW5iF

PS1-82
Modeling cisplatin resistance in testis cancer with the zebrafish
John T Lafin, PhD, University of Texas Southwestern Medical Center
Dreaux Abe, Murtaza Ahmed, Anna Savelyeva, PhD, Douglas W Strand, PhD, James F Amatruda, MD, PhD, Aditya Bagrodia, MD
https://drive.google.com/open?id=1v7D8Kl9qdssbjTbP_sI5me8MUT-XHsaI

PS1-83
Bladder cancer metabolomics identifies important differences in lipid metabolites between metastatic and non-metastatic tumors
Maria-Malvina Tsamouri, DVM, MSc, PhD student, UC Davis
Marc A. Dall’ÁEra MD, Shamira Sridharan PhD, Blythe P. Durbin-Johnson PhD, Sili Fan PhD, Paramita M. Ghosh PhD
https://drive.google.com/open?id=14xDu9e9UkqHiSUtl7hWsaP8HTWkWz9Ot

PS1-84
Androgen deprivation promotes neuroendocrine prostate cancer by activating Wnt/βCatenin signaling
Siyuan Cheng, Graduate Assistant-Research, LSUHSC-Shreveport
Shu Yang, Research Associate, Zachary Connelly, Ph.D., Xiuping Yu, Associate Professor
https://drive.google.com/open?id=1-XvT2Bqj8-7JRlbqC3c7sZlmWTNb50

PS1-85
Synergistic anticancer efficacy of simvastatin and metformin on enzalutamide resistant prostate cancer cells
Eswar Shankar, Case Western Reserve University
Che Jarvis, Sanjay Gupta, PhD
https://drive.google.com/open?id=1Q3dt3YIN9Jl63O8ng5ZaaKE0JGjamq77

PS1-86
Interaction between cancer cells and bone microenvironment in the bone metastatic progression of prostate cancer
Renjie Jin, MD, PhD, Vanderbilt University Medical Center
Tom Case, BS; Marisol Ramirez-Solano, MS; Alyssa Merkel, MS; Xinchun Zhou, MD, PhD; Qi Liu, PhD; Julie A. Rhoades, PhD
https://drive.google.com/open?id=1lpwE-GY7iqzidFDu5YfiZB7bIbObAGe

PS1-87
Extranuclear Nucleolin Induces ITGα6 expression in Prostate Cancer Independent of Androgen Receptor
Elsa Merit Reyes-Reyes, University of Arizona
Sara Moore, and Cindy K. Miranti
https://drive.google.com/open?id=1nK0Qhgqf9FwWqDqoxQa1M6Pm6UZp
**PS1-88**
Mechanism and Targeting the Hippo/YAP and NF-Kappa B/RELA Axis in Prostate Cancer Cells
Bekir Cinar, Ph.D., Associate Professor, Center for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University; Winship Cancer Institute, Emory University
Elijah Said-Bandy, Undergraduate Student, Center for Cancer Research and Therapeutic Development, Clark Marwa Al-Mathkour, PhD Student, Center for Cancer Research and Therapeutic Development and Department of Biological Sciences, Atlanta University; Carlos S. Moreno, PhD. Associate Professor, Department of Pathology and Laboratory Medicine and Biomedical Informatics, Emory University School of Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia
https://drive.google.com/open?id=1O5_x3vnYFzBrkJWF5L4mEA6xYBKyovsn

**PS1-89**
Studying Nanoparticle targeting to Prostate Cancer by using Quantum dot Antibody conjugate
Amarnath Mukherjee, Albert Einstein College of Medicine
Augene Park, Mark Schoenberg & Kelvin Davies
https://drive.google.com/open?id=1VEkJY9z9Gdr69qEsUM7zuTcsmmR0nH8E
PS2-01  
Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia  
Kent L. Nastiuk, Ph.D., Assistant Professor of Oncology, Department of Cancer Genetics & Genomics and Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA  
Chunliu Pan, Ph.D, Department of Cancer Genetics & Genomics, RPCCC, Neha Jaiswal, Ph.D., Department of Cancer Genetics & Genomics, RPCCC, Yanni Zulia, B.S., Department of Cancer Genetics & Genomics, RPCCC, Shalini Singh, Ph.D., Department of Cancer Genetics & Genomics, RPCCC, James L. Mohler, M.D., Department of Urology, RPCCC, Kevin H. Eng, Ph.D., Department of Biostatistics & Bioinformatics, RPCCC, Joe V. Chakkalakal, Ph.D., Departments of Pharmacology and Physiology, and Biomedical Engineering, University of Rochester Medical Center, Rochester, New York, USA, John J. Krolewski, M.D., Ph.D., Department of Cancer Genetics & Genomics, RPCCC  
https://drive.google.com/open?id=1IsPcadsoMwtowy4I1d2el2r6ldYBGpWY

PS2-02  
Determining the Roles of DNA Repair Gene Aberrations in Driving the Development and Progression of Prostate Cancer  
Sander Frank, PhD, Fred Hutchinson Cancer Research Center  
Dmytro Rudoy, Olga Klezovitch, PhD, Valeri Vasioukhin, PhD, Peter Nelson, MD  
https://drive.google.com/open?id=1kBE5fmxMyhPQbsSj4F6yHtGviOVOIU

PS2-03  
Synthetic Lethal Metabolic Targeting of Androgen Deprived Prostate Cancer Cells with Metformin  
Bing Yang, PhD Researchers, Department of Urology, University of Wisconsin-Madison  
Shivashankar Damodaran, MD, Surgery resident. Department of Urology, University of Wisconsin-Madison  
Tariq A. Khemes, MD, Urologic Oncology Fellow, Department of Urology, University of Wisconsin-Madison  
Mikolaj J. Filon, MD Candidate, School of Medicine and Public Health, University of Wisconsin-Madison  
Joseph Gawdzik, PhD, Department of Urology, University of Wisconsin-Madison  
Tyler Etheridge, MD, Department of Urology, University of Wisconsin-Madison  
Dmitry Malin, PhD, Scientist, Department of Medicine, University of Wisconsin-Madison  
Kyle Richards, MD, Assistant Professor, Department of Urology, University of Wisconsin-Madison  
Vincent L. Cryns, MD, Professor, Department of Medicine, University of Wisconsin-Madison  
David F. Jarrard, MD, Professor, Department of Urology, Carbone Comprehensive Cancer Center, Molecular and Environmental Toxicology Program, University of Wisconsin-Madison  
https://drive.google.com/open?id=1rp6D1kXkjlwlvJvbNuo-rsfJtWKh7ENP

PS2-04  
Targeting activation of AMPK suppresses PCa proliferation by regulating lipogenesis with subsequent inhibition of AR expression and activity  
Takuma Uo, PhD, University of Washington  
Gayani Perera, PhD, Kayode K Ojo, PhD, Wes Van Voorhis, MD, PhD J. Dustin Maly, Ph.D, Cynthia Sprener PhD  
https://drive.google.com/open?id=1CcFTuWbEUNutcQ59aEN0Wo_K3yR1Vc9z

PS2-05  
Investigating the Role of Rbl2 in Castration-Resistant Prostate Cancer  
Jenna Giafaglione, University of California, Los Angeles  
Andrew Goldstein, PhD, Paul Boutros, PhD  
https://drive.google.com/open?id=1YO22Ju6leeRUPBorR4jc0Eg3lUexkuRp
PS2-06
Genetics features of Localized Prostate Cancer in African Americans
Naoya Nagaya, Rutgers Cancer Institute of New Jersey
Jeffrey Rosenfeld, Geuntaek Lee, Isaac Kim
https://drive.google.com/open?id=1oUmAtvDRwq-oUQaD8qqQoq1eTMhvsddl

PS2-07
Sulfotransferase SULT2B1b inhibition potently stimulates the expression of immunomodulatory genes in prostate cancer cells
Jiang Yang, Ph.D., Purdue University
Renee E. Vickman Ph.D., Meaghan M. Broman, D.V.M. Sagar Utturkar, Ph.D., Nadia A. Lanman, Ph.D., Timothy L. Ratliff, Ph.D., Professor
https://drive.google.com/open?id=1ZiYNCHB04nUyDV6A3MfeFWP16j4x-cIR

PS2-08
Modulation of the Prostate Tumor Microenvironment by Folate-mediated Targeting of Tumor Resident Myeloid Populations
Dr. Gregory Cresswell, Purdue University
Dr. Meaghan Broman, Rami AlFar Dr. Phillip S. Low, Dr. Timothy L. Ratliff
https://drive.google.com/open?id=1r5RGf_sAqZz4ArARjsO3wnr3hr6Xw6jF

PS2-09
Putative tumor suppressor ELL2 is required for proliferation and survival of AR-negative prostate cancer cells
Zhi Wang, MS, University of Pittsburgh
Laura E. Pascal, Ph.D.Uma R Chandran, Ph.D. Srilakshmi Chaparala, MSSHidong Lyu, MS Hui Ding, Ph.DLin Qi, Ph.D, Zhou Wang, Ph.D
https://drive.google.com/open?id=14dvIQL0kyrnmT2HyUpr49A KstaWUg36kZ

PS2-10
Novel Roles for Manganese Superoxide Dismutase Polymorphisms in Prostate Cancer
Janae D. Sweeney, Ph.D. Student, Clark Atlanta University
Channing Paller, M.D.; Assistant Professor of Oncology and Urology- Johns HopkinsValerie Odero-Marah, Ph.D.; Associate Professor of Biological Sciences- Clark Atlanta University
https://drive.google.com/open?id=1RGgt711GJK_03bV1cmrsOEs7HQja5UmU

PS2-11
Neuroendocrine Marker improves the diagnosis of Prostate Cancer
Johnmesha L. Sanders, University of Louisiana at Monroe
Ajay Kale, Ph.D. Girish V. Shah, Ph.D.
https://drive.google.com/open?id=1aDKlxh2yT619NSC7uZm6STMtk75Bn3wm

PS2-12
GWAS and CNV analysis Demonstrate Polygenic Determination of Vesicoureteral Reflux
Miguel Verbitsky, Ph.D., Columbia University
Priya Krithivasan, MSc; Atlas Khan, PhD; Maddalena Marasa, MD; Byum hee Kil, MSc; Adele Mitrotti, MD; Matt G. Sampson, MD; Monica Bodria, MD; Loreto Gesualdo, MD; Giuseppe Masnata, MD; Francesco Scolari, MD; Rik Westland, MD; Joanna Van Wijk, MD; Marijan Saraga, MD; Domenico Santoro, MD; Pasquale Zamboli, MD; Craig S. Wong, MD; Enrico Fiaccadori, MD; Friedhelm Hildebrandt, MD; John M Darlow, MD; David E Barton, MD; Velibor Tasic, MD; Anna Latos-Bielenksa, MD; Anna Materna-Kiryuk, MD; Krzysztof Krylik, MD; Simone Sanna-Cherchi, MD; Jonathan Barach, MD PhD; Cathy Mendelsohn, PhD; Ali G. Gharavi, MD
https://drive.google.com/open?id=1VEgWBqzjSQC0nxVqXGHe7Yggeoe8bjX

PS2-13
SLX4IP is Essential for Telomere Maintenance in Neuroendocrine Prostate Cancer
Tawna L. Whited, Department of Pharmacology, Case Western Reserve University
Wisam N. Awadallah, Department of Urology, Case Western Reserve UniversityMagdalena M. Grabowska, Department of Urology, Case Western Reserve UniversityDerek J. Taylor, Department of Pharmacology, Case Western Reserve University
https://drive.google.com/open?id=1ggxKbwfa2RjAh5MMz4d pa9bvjkl3D6

PS2-14
DNA methylation and DNA methyltransferases contribute to enzalutamide resistance in prostate cancer
Elia Farah, PhD, Purdue University
Lijun Cheng, PhD. Tim Ratliff, and PhD. Xiaqi Liu
https://drive.google.com/open?id=1fewPC09ShckqgieOukvl_pOsPdoczQI
PS2-15
Inhibition of EphB4 overwhelms enzalutamide resistance by antagonizing the amplification of AR
Chaohao Li, University of Kentucky
Dr. Xiaoiq Liu
https://drive.google.com/open?id=1D1FxVLdJkDMShS0dQ97bPWnO--t8gV

PS2-16
Immune Cell Interactions in Benign Prostatic Hyperplasia
Meaghan M Broman D.V.M., Purdue University
https://drive.google.com/open?id=1ux78rTpgAydJQ8rC2Qnvulsh0

PS2-17
Single Cell Analysis of Luminal Epithelial Cells in the Castrate Prostate Reveals a Unique Population of Candidate Luminal Progenitors
Daniel Moline, University of Chicago
Dr. Donald Vander Griend
https://drive.google.com/open?id=1tEYs6uz5x21NRNy1ZQ0E42eAGBDQ8zo

PS2-18
African American prostate cancer stroma exhibits higher levels of secreted TGF-beta1 and overexpresses GARP but presents with more infiltration of cytotoxic CD8 (+) T cells
Liankun Song, Department of Urology, University of California, Irvine
Shan Xia, Associated Professor of Pathology, Agrawal, Sudhanshu, Project Scientist, Farah Rahmatpanah, Project Scientist, Yuanjie Hu, Assistant Professor of Medicine and Immunology, Anshu Agrawal, Associated Professor of Medicine and Immunology
https://drive.google.com/open?id=1ECdSYsZUbGylkBxkxxnYeH0hH8y4kVn3

PS2-19
Mediating EGFR- and ERK-Dependent Enzalutamide-Resistance in Castration-Resistant Prostate Cancer
Thomas M. Steele, UC Davis Medical Center
Maitreyee K. Jathal, Ph.D, Saif A Siddiqui, M.D; Sisi Qin, Ph.D; Xiaobo Shi, Ph.D; Dr. Clifford G. Tepper, Ph.D; Ralph W. deVere White, M.D; Manish Kohli, M.D; Liewei Wang, M.D, Ph.D; Allen C. Gao, M.D; Ph.D; Paramita M. Ghosh, Ph.D
https://drive.google.com/open?id=1Ur9J15oQYmvH837QASfb2HTYKv7kSLU

PS2-20
Radiation cystitis modeling: a comparative study of radiation induced bladder fibrosis in different mouse strains
Laura E. Lamb, PhD, Beaumont Health/ Oakland University
William Beaumont School of Medicine
Bernadette M. M. Zwaans, Ph.D; Kyle A. Wegner, BS; Sarah N. Bartolone, MS; Chad M. Vezina, PhD; Michael B. Chancellor, MD; Laura E. Lamb, PhD
https://drive.google.com/open?id=1sBGN6rPlxtiCN2mfb6GQyWNlwEJHvM

PS2-21
Low concentration BPA, BPS and BPF exposure: genotoxic effect in prostate cancer.
Sergio Alberto Cortes Ramirez, PhD student, Universidad Nacional Autonoma de Mexico (UNAM)
PhD Ana Maria Salazar Martinez , PhD Martha Patricia Ostrosky, Shejiet, BS Laura Daniela Palomino Navarrete PhD student Jenie Mariana Cruz Burgos, PhD student Carlos David Cruz Hernandez, PhD student Alberto Lozada Garcia, PhD
https://drive.google.com/open?id=1OAkKO-60abSUvXy7zQADnJ0E_tClvEaf

PS2-22
Combination therapy of cisplatin and siRNA GP130 impacts a DNA repair mechanism in bladder cancer
Darryl T. Martin, PhD, Research Scientist, Yale University
Shanshan He, MD, Visiting Scholar, Yale University; Gang Li, PhD, Visiting Graduate Student, Yale University; Andreas G. Schützelein, PhD, Professor of Translational Therapeutics, UCL School of Pharmacy; Robert M. Weiss, MD, Donald Guthrie Professor of Urology, Yale University; and Ijeoma F. Uchegbu, PhD, Professor of Pharmaceutics, UCL School of Pharmacy
https://drive.google.com/open?id=1DaiapmmXOT_vcmF2mQq2cfaUB0oCD

PS2-23
Sprr2f quenches ROS to protect against ischemia-reperfusion injury in the mouse kidney
Kieu My Huynh, M.S, Stanford University, Department of UROLOGY
Marc Horschman, B.S, Bo Wu, PhD, Anny Wong, PhD, Rosie Nolley, B.S, Hongjuan Zhao PhD, James D. Brooks, MD, Principal Investigator
https://drive.google.com/open?id=1uWDuD7Tvy6Zbe2z2pa2Bt33tJmYNNfS
PS2-24
Targeting telomere DNA damage for CRPC therapy
Sahn-ho Kim, Assistant Scientist, Henry Ford Health System
https://drive.google.com/open?id=1mgfu7C4Odu64nWwqNOC_9QoqTrTbDv1

PS2-25
Arsenic Disturbs Prostate Stem-progenitor Cells Homeostasis by Activation of NRF2 Pathway
Dan-Ping Hu, MD, University of Illinois
Lishi Xie, PhD; Wen-Yang Hu, PhD, MD; Dan-Ping Hu, MD; Ye Li, BS; Lynn Birch, MS; Gail S. Prins, PhD
https://drive.google.com/open?id=1EwYxnvf_ZGhj8zW7ynW4U0tgHfZAY5Y

PS2-26
Bone-resident neutrophils are mediators of prostate cancer growth in bone
Leah M. Cook, PhD, University of Nebraska Medical Center
Diane Costanzo-Garvey, Tyler Keeley, PhD, Adam Case, PhD, Leah M. Cook, PhD
https://drive.google.com/open?id=13ZkehDWTT5D8v4wwRuwAHBeYXdrw-6tP

PS2-27
Modulating HSP70/STUB1 machinery by novel small molecules overcomes enzalutamide resistance in lethal prostate cancer
Chengfei Liu, MD, PhD, University of California, Davis
Wei Lou, MD, Joy C. Yang, PhD, Shu Ning, MS, Cameron M. Armstrong, PhD, Alan P. Lombard, PhD, Leandro S D’Abronzo, PhD, Clifford Tepper, PhD, Pui-Kai Li, PhD, Christopher P. Evans, MD, Allen C. Gao, MD, PhD
https://drive.google.com/open?id=1rVBvqdRE0wncBP5c7jXLIT0SsNnvH5S2

PS2-28
The Trained Immunity-like Epigenetic Memory in Urinary Tract Infection
Chunmin Guo, Boston Children’s Hospital, Harvard Medical School
Mingyi Zhao, Songhui Zhai, Xinbing Sui, Zarine Balsara, Hyunwoo Kwon, Zihai Li and Xue Li
https://drive.google.com/open?id=18Bo3dgSC2cCzPa7wk1MA Dq1k7MmGlFTu

PS2-29
Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Sandra Santasuagena, PhD, Thomas Jefferson University
https://drive.google.com/open?id=18UjqinP18qqYAqKum7Pz tWCUTUHGH8z

PS2-30
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer
Ping Mu, Assistant Professor, UT Southwestern Medical Center
Zeda Zhang1,3,*, Chuanli Zhou2,*, Xiaoling Li2,*, Spencer Barnes4, Su Deng2, Elizabeth Hoover1, Chi-Chao Chen5,6, Young Sun Lee1, Chouhsi Wang2, Carla Tirado2, Lauren Metang2, Yanxiao Zhang7, Nick Johnson2, John Wongvipat1, Kristina Navrazhina6, Zhen Cao5,6, Eliot Linton1, Dapeng Yun2, Xiaoping Chen8, Yupu Liang9, Christopher E. Mason10,11, Elisa de Stanchina8, Wassim Abdai12, Amaia Lujambio14, Ashutosh Tewari, W. Kevin Kelly, Benjamin E. Leiby, Josep Maria Prats7, Leonard Gomella, Josep Domingo-Domenech
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA2. Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA3. Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA4. Bioinformatics Core Facility of the Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA5. Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 6. Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA7. Ludwig Institute for Cancer Research, La Jolla, CA, USA8. Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA9. Center for Clinical and Translational Science, Rockefeller University, New York, NY 10065, USA10. Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA11. The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA12. The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, USA13. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA14. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA15. The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.16. Howard
PS2-31
Single Cell Investigation of Patient-Derived Prostate Organoids Reveals Differentiation Protocol Involving Epithelial Integrin Expression Supported by Stromal Collagen
Tara McCray, University of Illinois at Chicago
Larisa Nonn, PhD
https://drive.google.com/open?id=16tg4RMU2lxw-96XmaClqUjB8duKFwK4

PS2-32
Vitamin D Inhibits DKK3 To Promote Human Prostate Organoid Differentiation
Tara McCray, University of Illinois at Chicago
Larisa Nonn, PhD, Bethany Baumann, PhD
https://drive.google.com/open?id=1Q45HNEAdliZaNlllyS_T_RKeZq8NVKe

PS2-33
Extragonadal androgen biosynthesis associated with variant HSD3B1 (A1245C) allele modulates radiosensitivity in Prostate Cancer cells
Omar Mian, MD, PhD, Cleveland Clinic Foundation
Shinjini Ganguly (PhD), Aysegul Balyimez (PhD), Zaeem Lone (BA), Aimalie Hardaway (PhD), Monaben Patel (MS), Elai Davicioni (PhD), Rahul Tendulkar (MD), Eric Klein (MD), Nima Sharifi (MD), Omar Mian (MD,PhD)
https://drive.google.com/open?id=1K8nEjDK0pf_fXMYwmrXPlma4dqVBKKJb

PS2-34
An orthotopic murine neuroendocrine bladder cancer model offers insights into the phenotypic plasticity of small bladder cancer cells (SCBC)
Omar Y. Mian, M.D., Ph.D, Assistant Professor, Cleveland Clinic
Aysegul Balyimez, Shinjini Ganguly, Sita Luxami, Petros Grivas, Moshe Ornstein, Shilpa Gupta, Byron Lee, Chris McFarland, Monte Winslow, Jesse McKenney
https://drive.google.com/open?id=1cLWAfcFzPk77Bj0dJUtOQ1HBeAjtUTdln

PS2-35
NAD+ metabolism as a potential vulnerability in neuroendocrine prostate cancer
Johnny A. Diaz, UCLA

PS2-36
Downregulation of EPHB2 Increases Alterations in Lipid Metabolism Associated with Prostate Cancer Racial Disparities
Omar Franco MD, PhD, NorthShore University Health System
Alejandro Morales BS, Francesca Nardi MS, Susan Crawford MD, Simon Hayward PhD
https://drive.google.com/open?id=1STer1-LepGkBGO_xPMHD3HPRJhqWF-Qp

PS2-37
Role of polyamine metabolism in prostate cancer therapy resistance
Nagalakshmi Nadiminty, PhD, University of Toledo Health Science Campus
Sayani Bhattacharjee, Jonathan P. Doan, Jerred P. Pletcher, Rebecca Wynn
https://drive.google.com/open?id=1tiKYUt3bDYRaywtY4dBQfdzb7A599O3g

PS2-38
BUB1B is a key component of an AR variant-regulated network in castration-resistant prostate cancer
Kerry L. Burnstein, Professor and Chair, Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine
Maria Julia Martinez, Post-doctoral Associate, Valeria A. Copella, Graduate Student, Rolando D.Z. Lyles, Graduate Student
https://drive.google.com/open?id=1qF_LDVjLCDRd_JS6JOLX8mfvLRL42fmo

PS2-39
Roles of retinoid signaling in the developing urothelium
Gregory Wiessner, Columbia University Medical Center
Dr. Ekatherina Batourina, Dr. Carolina Rosselot, Dr. Chad Vezina, Kerry Schneider, Dr. Cathy Mendelsohn
https://drive.google.com/open?id=1plBAdpfun4aoEocTwh41W5kUcnX77br

PS2-40
Role of SLCO1B3 Transporter in Prostate Cancer Cell Resistance to Cabazitaxel Chemotherapy
Diane Begemann, University of Kentucky
Natasha Kyprianou, PhD
https://drive.google.com/open?id=155VxU0tdAwYuyQWvmA00zl8tzoqer8g
PS2-41
PB-Csf1 is a novel mouse model for prostate inflammation
Li Xin, University of Washington
Ohjoon Kown, Boyu Zhang, Li Zhang, Xing Wei, and Li Xin
https://drive.google.com/open?id=1RQEI5mCWAjwY56UUaUdqNe_ocgOLfqd

PS2-42
Adipocyte-dependent lipid/MTOC dysregulation in the prostate tumor microenvironment: A microfluidic approach
Max Greenberg, Research Associate, NorthShore Univ. Research Institute, Affiliate of Univ. of Chicago Pritzker School of Medicine
Victoria Gil, Research Associate, John Day, Graduate Student, Univ. of Washington, Omar E. Franco, Research Scientist, Francesca Nardi, Research Scientist, Philip Fitchev, Research Associate, Simon W. Hayward, Director of Cancer Biology, Ashleigh Theberge, Assistant Professor, Univ of Washington, Susan E. Crawford, Professor of Pathology
https://drive.google.com/open?id=1ONYHi_hngP5zfU27pGRnxLhaGx0x8gLW

PS2-43
Targeting the WNT5A Receptor, ROR1, in Prostate Cancer
Christina A.M. Jamieson, PhD. Associate Professor, Dept of Urology, University of California, San Diego (UCSD)
Sanghee Lee, Neurourology Fellow UCSD Urology, Danielle N Burner, Lab Technician, Theresa R Mendoza, MSc student, Michelle T Muldong, Senior Research Associate, Abril Zuniga, Undergraduate Albert Scholar, Catalina Arreola, Lab Technician, Christina N Wu, Senior Project Scientist, John J McDermott, Medical student and Albert Scholar, Rekha S Narasiman, Medical student and Albert Scholar, SungKu Kang, Visiting Scholar, Catriona HM Jamieson, Professor, Nicholas A Cacalano, Associate Professor, Isaac Y Kim, Professor, Karl Willert, Professor, Terry Gaasterland, Professor, Anna A Kulidjian, Associate Professor, Rana Mckay, Assistant Professor, Christopher J Kane, Professor
https://drive.google.com/open?id=1omKJZK6igY0PoUYzRpt40pKbX0vClnA

PS2-44
Interactions between prostate hormone levels, African ancestry, and gene expression patterns in stroma and epithelium
Bethany Baumann, PhD, University of Illinois at Chicago
Julian Pacheco, Zachary Richards, PhD, Jason Garcia, Rick Kittle, PhD, Larisa Nown, PhD
https://drive.google.com/open?id=1JygsKOx96Dj4MeUeUxU5a0FVYZsc43nF

PS2-45
Resistance to AR Signaling Inhibition Does Not Necessitate Prostate Neuroendocrine Differentiation
W. Nathaniel Brennen, Johns Hopkins
Yezi Zhu2, Ilsa Coleman3, Susan Dalrymple1, Lizamma Antony1, Alan Meeker1,2, S. Lilly Zheng5, Jody E. Hooper4, Jun Luo2, Angelo De Marzo1,2,4, Eva Corey5, Jianfeng Xu5, Peter S. Nelson3,6, William B. Isaacs2, John T. Isaacs1,2,4Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University, Baltimore, MD 21205, USA. 2Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 3Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 4Department of Pathology, SKCCC, Johns Hopkins University, Baltimore, MD 21205, USA. 5Program for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA. 6Department of Urology, University of Washington, Seattle, WA 98195, USA
https://drive.google.com/open?id=1Dssdb3G_XSTCd6YHw5uHxZIYSPV06JsZ

PS2-46
Integrin a6b1 super agonist overcomes drug resistance in castration-resistant prostate cancer by targeting laminin adhesion
Marina Cardo Vila, PhD, University of Arizona Cancer Center
Eric A. Nollet PhD, Sourik S. Ganguly PhD, Veronique V. Schulz BS, Scott Peterson PhD, Anne Cress PhD Eva Corey PhD, Cindy K. Miranti PhD
https://drive.google.com/open?id=1kgvHtASJ7cFjmie3f5BF5wQz55cRd8-3

PS2-47
The Role of IL33 in Microbial Induced Prostate Fibrosis
Ashlee Bell-Cohn, Northwestern University
Praveen Thumbikat, PhD, DVM
https://drive.google.com/open?id=1B0J6Affrts13SgjhEzj5de71FVupyHNl
**PS2-48**
Characterization of the Metabolomic Profile of Prostate Cancer by Capillary Electrophoresis Mass Spectrometry of Urine
Andrew Gusev, BA, Massachusetts General Hospital
Alex Buko, PhD, Takushi Oga, PhD, Adam S. Feldman, MD, MPH, Leo L. Cheng, PhD
https://drive.google.com/open?id=1_Rsldh2XrYU8hrRqmX7lwEWFk9nyh3T

**PS2-49**
Effect of the SFRP1 protein on prostate cancer stem cells populations
Alberto Losada-Garcia, MSc., UNAM
Marian Cruz-Burgos, B.D., Sergio Cortes-Ramirez, QFB., Carlos Cruz-Hernandez, MSc., Mauricio Rodriguez-Dorantes, Ph.D.
https://drive.google.com/open?id=1La5cQeql0PwyWrpVAK2DoJFgHlHgWee

**PS2-50**
FOXA2 Promotes Prostate Cancer Growth in Bone
Zachary M. Connelly, LSUHSC Shreveport
Renjie Jin2, Jianguo Zhang2, Shu Yang1, Siyuan Cheng1, Mingxia Shi3, Justin Cates4, Runhua Shi5, David J. DeGraff6, Peter S. Nelson7, Yunlong Liu8, Colm Morrissey9, Eva Corey9, Xiuping Yu1*1Dept of Biochemistry and Molecular Biology, 3Dept of Pathology, 5Dept of Medicine, LSU Health Sciences Center, Shreveport, LA; 2Dept of Urology, Vanderbilt University Medical Center, Nashville, TN; 4Dept of Pathology, Vanderbilt University Medical Center, Nashville, TN; 6Dept of Pathology, Pennsylvania State College of Medicine, Hershey, PA; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, IN; 9Dept of Urology, University of Washington, Seattle, WA
https://drive.google.com/open?id=1c5xNunWkhq5WEXgFahRFd96Fz6CwF

**PS2-51**
Loss of CDCP1 promotes FAK activation in the detached state
Sara Pollan, PhD, Cedars-Sinai Medical Center
Beatrice Knudsen, MD, PhD
https://drive.google.com/open?id=1U-I6Hxz1FjcdCTZMR8qNChQYFpsXit

**PS2-52**
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
Wenliang Li, Associate Professor, University of Texas Health Science Center at Houston
Yan Zhang, Dayong Zheng, Ting Zhou, Haiping Song, Mohit Hulsurkar, Zheng Wang, Shao Long, Ladan Fazli, Michael Ittmann, Martin Gleave, Wenliang Li
https://drive.google.com/open?id=1pNjZso80D0wvj_AaYzjItDq4ILa54G

**PS2-53**
Effect of radiation cystitis on urinary bladder mechanics
Marissa Grobbel, Ph.D. Student in Mechanical Engineering at Michigan State University
Bernadette M.M. Zwaans, Elijah P. Ward, Laura E. Lamb, Department of Urology, Beaumont Health and Sara Roccabianca, Mechanical Engineering Professor at Michigan State University
https://drive.google.com/open?id=1ZzAajfBl8unV4g1SJrb7jKeFaT_BbkSr

**PS2-54**
Pharmacogenetic inhibition of afferent excitability alleviates VEGF-induced visceral allodynia and hyperalgesia in a mouse model of urological chronic pelvic pain syndrome (UCPPS)
Alison Xiaoqiao Xie, Ph. D. Instructor, Division of Urology, Department of Surgery, UC Denver
Randall B. Meacham, M.D., Professor, Chair of the Division of Urology, Department of Surgery, UC Denver; Anna P. Malykhina, Ph. D. Associate Professor, Division of Urology, Department of Surgery, UC Denver
https://drive.google.com/open?id=1Q-3B2wlm1cS3nBXKemOFhe2oucTusy-

**PS2-55**
Identification of multipotent prostate basal stem cells from single-cell RNA sequencing
Helen He ZHU, Professor, Shanghai Jiao Tong University
Xue Wang, Ph.D. candidate; Wei-Qiang Gao, Professor
https://drive.google.com/open?id=1fZa69sh0ux8liP1bK8ke2BscsL7FxocCb
PS2-56
PRMT5 as a novel target for the treatment of castration-resistant prostate cancer
Elena Beketova, MS, Purdue University
2019 Travel Award Winner
Jake Owens, BA, Xuehong DengChang-Deng Hu, PhD
https://drive.google.com/open?id=1DbfnIlPto1aruAlEN6CrOIZhUg8jpfK

PS2-57
Transcription factor PROX1 drives neuroendocrine differentiation and cellular plasticity in prostate cancer
Kajjie Wu, M.D., Ph.D., Associate Professor, Department of Urology, First Affiliated Hospital of Xian Jiaotong University
Ke Hui, M.D., Ph.D., Shiqi Wu, M.D., Ph.D. candidate Yanan Gu, M.D., Ph.D. candidate, Dalin He, M.D., Ph.D., Professor
https://drive.google.com/open?id=1MtlxXmfgzMlpvVMnHViQAWVVU92cw6Q

PS2-58
Site Specific DNA Methylation Silences Forkhead Box A1 Expression in Advanced Bladder Cancer
Jenna M. Buckwalter, Ph.D., Penn State Hershey College of Medicine
2019 Travel Award Winner
Lauren M. Shuman M.S., Thomas C. Wildermuth, Vonn Walter Ph.D., Joshua Warrick M.D., Xue-Ru Wu M.D., Jay Raman M.D., David J. DeGraff Ph.D.
https://drive.google.com/open?id=1w78Au9Dn_yRAw5rbFde7ossAkauoOfNCMhdmNHe9k

PS2-59
A novel non-canonical EZH2 function as a chaperone to mediate box C/D snoRNP assembly
Yang Yi, Post-Doctoral Fellow, Northwestern University
2019 Travel Award Winner
Qingshu Meng, Post-doctoral fellow; Qiaqia Li, Graduate Student; Kaifu Chen, Associate Professor; Wei Zhao, Professor; Qi Cao, Associate Professor
https://drive.google.com/open?id=1nl1YkYQGelmP_ThnfRN5yuf3r_vJQabW

PS2-60
Repression of Transcription Factor AP-2 Alpha by PPAR gamma Reveals a Novel Transcriptional Circuit in Basal-squamous Bladder Cancer
Hironobu Yamashita, Penn State Hershey Medical Center
Yuka I. Kawasawa, Lauren Shuman, Zongyu Zheng, Truc Tran, Vonn Walter, Joshua I. Warrick, Guoli Chen, Hikmat Al-Ahmadie, Matthew Kaag, Pak Kin Wong, Jay D. Raman, David J. DeGraff
https://drive.google.com/open?id=14r8VBYzdl3mogqH8DFkkrRhIA6ogzM

PS2-61
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
Nicholas J. Brady, Weill Cornell Medicine
2019 Travel Award Winner
https://drive.google.com/open?id=1PMzw1hllgWHpFOT3xLG8ssHO-kzCiHSPb84EvqR-H0

PS2-62
Fibroblast growth factor receptor 1 in reprogramming cell metabolism in prostate cancer cells
Fen Wang, Ph. D., Texas A&M University
Ms. Yuepeng Ke, Mr. Ziying Liu, Dr. Sheng Pan
https://drive.google.com/open?id=1H8uVsfBt6YnU0-Pb2Mio1r966yHL2b
PS2-63
Identification of cognate proximal cell types of the mouse and human prostate and their enrichment in human Benign Prostatic Hyperplasia
Diya Binoy Joseph, UT Southwestern Medical Center
2019 Travel Award Winner
Gervaise Henry, Department of Urology, UT Southwestern Medical Center, Alicia Malewska, Department of Urology, UT Southwestern Medical Center, Kyle Wegner, School of Veterinary Medicine, University of Wisconsin-Madison, Claus Roehrborn, Department of Urology, UT Southwestern Medical Center, Jeffrey Reese, Southwest Transplant Alliance, Dallas, Ryan Hutchinson, Department of Urology, UT Southwestern Medical Center, Chad Vezina, School of Veterinary Medicine, University of Wisconsin-Madison, Douglas Strand, Department of Urology, UT Southwestern Medical Center
https://drive.google.com/open?id=1I1ChnZC7w5-dG43Ql8

PS2-64
PBRM1 mutation develops a tumor-favoring microenvironment in renal cell carcinoma
Shan Xu, M.D, The First Affiliated Hospital of Xian Jiaotong University
Katie Wu, ph.D, Lei Li, Ph.D, M.D
https://drive.google.com/open?id=14wLaZCeX0lubAN8_QstUN7NP6GCFKdx

PS2-65
FKHD-Mutant FOXA1 Promotes Androgen Independence and Prostate Cancer Progression
Xiaodong Lu, PhD, Northwestern University
Bohan Xu, PhD; Bing Song, PhD; Jung Kim, PhD; Ming Hu, PhD; Jonathan C. Zhao, PhD; Jindan Yu, PhD
https://drive.google.com/open?id=1pp7d5pNuZmFgQRh4v2y9aciG6bUS0m8z

PS2-66
Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) is upregulated in PCa and promotes resistance to androgen deprivation therapy
Praveen Kumar Jaiswal, Postdoctoral Fellow, LSUHSC-Shreveport
2019 Travel Award Winner
Sweaty Koul, Kashyap Koul, Runhua Shi, Hari K Koul
https://drive.google.com/open?id=12DpfPQlbnEjRjQxIhiq8yCXdQh9PeDyH

PS2-67
NOX4 is upregulated during PCa progression and plays a key role in hypoxic survival of PCa cells
Saikolappan Sankaralingam, LUSMSC-Shreveport
Binod Kumar, Sweaty Koul, Praveen Kumar Jaiswal, Hari K Koul
https://drive.google.com/open?id=1sW1ac7HxCGMOxCE1NXw2qa9mGqsc7BOTM

PS2-68
Androgen-sensitive differential expression of cytokines and growth factors in primary BPH stromal cells and normal adjacent stromal cells
Wei Chen, Ph.D, University of Pittsburgh
Laura E. Pascal, Ph.D, Zhou Wang, Ph.D., Rajiv Dhir, MD, Uma Chandran, Ph.D, Zhou Wang, Ph.D, Alex Chang
https://drive.google.com/open?id=1Jj5p4K8EAMGjnDMItGVa0NtNC6q3eA5

PS2-69
Effect of new AR-V7 inhibitor in enzalutamide resistant prostate cancer
Geun Taek Lee, Ph.D., Rutgers Cancer Institute of New Jersey
Naoya Nagaya, MD, Roy J. Vaz, Ph.D., Isaac Yi Kim, MD, Ph.D., MBA
https://drive.google.com/open?id=1ZSKVmYJNwpHf2h_rhyFzRGECN79vuHNM

PS2-70
Osteopontin exacerbates the inflammatory environment in the prostate
Petra Popovics PhD, University of Wisconsin-Madison
2019 Travel Award Winner
Wisam N. Awadallah BS, Sarah Kohrt BS, Thomas C. Case BS, Nicole L. Miller MD, Emily Ricke MS, Marisol Ramirez-Solano MS, Qi Liu PhD, Robert J. Matusik PhD, William A. Ricke PhD and Magdalena M. Grabowska PhD
https://drive.google.com/open?id=1M0AEItspc1Tci6gZup3X3VgsppNOJ2myGA7pXVIGxXg

PS2-71
Identification of genes that drive resistance to enzalutamide in castration-resistant prostate cancer cells
Wisam Awadallah, Case Western Reserve University
Sarah Kohrt, Robert A. Philips, Renjie Jiu, Xiuping Yu, Jianghong Zhang, Tom C. Case, Peter E. Clark, Robert J. Matusik, Yajun Yi Philip D. Anderson, Magdalena M. Grabowska
https://drive.google.com/open?id=1KxluuAaH-7zuuy4vylyJhf_p00lQW121
PS2-72
Role of Estrogens in Fibrosis and Myofibroblast Phenoconversion of Prostate Stromal Cells
Christian J. Ortiz Hernandez, Graduate Student, University of Wisconsin-Madison
William A. Ricke, UWMF Professor of Urologic Research and Director of the George M. O’Brien Center for Benign Urology Research
https://drive.google.com/open?id=10KVicFI6xMsCnE2LZIXTEGmUj-Ng-7S

PS2-73
Novel role of ketone body metabolism in acquired gemcitabine resistance
Krizia Rohena Rivera, PhD, Cedars Sinai Medical Center
Neil Bhowmick, PhD
https://drive.google.com/open?id=1E_aLKWJT9hl_K1yh4g4Wz9rA2NoPV

PS2-74
Tumor Microenvironment Characterization in Bladder Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures
Tianjie Liu, Department of Urology Research Institute, First Affiliated Hospital of Medical School, Xi’an Jiaotong University
Jin Zeng, Kaijie Wu, Yule Chen, Shan Xu
https://drive.google.com/open?id=1I-YseEJNxWv7i1fBge8ngOot_NO45E

PS2-75
SPINK1 is associated with androgen independence in prostate cancer cells
Ikenna Maduweke, MD., Ph.D., University of Illinois at Chicago
Wen-Yang Hu, MD,Ph.D.,Lishi Xie, Ph.D, Donald Vander Griemd, Ph.D, Michael R. Abern, MD, Gail S. Prins, Ph.D.
https://drive.google.com/open?id=1mYvQENHblXWOoh3hOSq8esgDOwS42kZ

PS2-76
Ferroptosis induction as a novel therapeutic approach for advanced prostate cancer
Ali Ghoochani, PhD, Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine
Fernando Jose Garcia Marques, PhD, Abel Bermudez, BSc. Merve Aslan, MSc. Meghan A. Rice, PhD, En-Chi Hsu, PhD, Sharon J. Pitteri, PhD. Eva Corey, PhD. James D. Brooks, MD. Tanya Stoyanova, PhD.
https://drive.google.com/open?id=1OSSXXbIXFkQnLmx116UnHHoSF4QJUNj

PS2-77
ONECUT2 and its Extremely Long 3’à-Non-coding Region Cooperate To Drive Aggressive Prostate Cancer
Kenneth Steadman, Cedars-Sinai Medical Center
Sun Yong You, PhD, Dustin Srinivas, PhD, Smruthi V. Venugopal, PhD, Yiwu Yan, PhD, Hisashi Tanaka, PhD Wei Yang, PhD, Michael R Freeman, PhD
https://drive.google.com/open?id=1oEmNh-5z9Hq3jf3NDjXXoF46MOxmA7U

PS2-78
Notch3 promotes Prostate Cancer-Induced Bone Lesion Development by Modulating the Bone Microenvironment via MMP-3.
Sourik S Ganguly, University of Arizona
Galen Hostetter, Lin Tang, Sander B. Frank, Kathlynn Saboda, Rohit Mehra, Lisha Wang, Xiaohong Li, Evan T. Keller, and Cindy K. Miranti
https://drive.google.com/open?id=1RyZlvYIXrMs33lIFQ-j3fucbf8A0leZ

PS2-79
CDK4/6 Pathway as Therapeutic Target for Bladder Cancer
Ai-Hong Ma, Ph.D., University of California Davis
Roger Xia, QiLai Long, M.D., Hongyong Zhang, Ph.D., Zhixiu Cao, M.D., Tzu-Yin Lin Ph.D., DVM, Guru P. Sonpavde, M.D., Ralph de Vere White, M.D., Jianmin Guo, M.D., Chong-Xian Pan, M.D., Ph.D.
https://drive.google.com/open?id=1hLHZa8PfJrGZ71Cx_4kef4HTK7UTrvs

PS2-80
PBM nano-formulation inhibits hedgehog signaling in docetaxel-resistant prostate cancer
Santosh Kumar Singh, Ph.D., Research Associate, Morehouse School of Medicine
James W. Lillard Jr. Ph.D., Professor, Morehouse School of MedicineRajesh Singh, Ph.D., Associate Professor, Morehouse School of Medicine
https://drive.google.com/open?id=1rQ7AKLPoaBszIGTERCsgMDVU8gw-sAr
**PS2-81**
The Role of SOX2 in Promoting Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Larischa de Wet, PhD Candidate, University of Chicago
Anthony Williams, Postdoctoral Scholar, University of Chicago, Marc Gillard, Postdoctoral Scholar, University of Chicago, Steven Kregel, PhD Candidate, University of Chicago, Ryan Brown, Research Specialist, University of Illinois at Chicago, Sophia Lamperis, Technician, University of Illinois at Chicago, Gladell P. Paner, Pathologist, University of Chicago, Russell Z. Szmulewitz, Associate Professor of Medicine, University of Chicago, Donald J. Vander Griend, Visiting Associate Professor, University of Illinois at Chicago

https://drive.google.com/open?id=1toY9yuoMy5pTIkJBzX1C5qtCPHV0gZu9

**PS2-82**
The effects of autoimmune inflammation on androgen receptor signaling in adult prostate stem cells

Paula O Cooper, Graduate Student, Purdue University
Hsing-Hui Wang, PhD, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC. Meaghan M. Broman, DVM, MS, DACVP, Department of Comparative Pathobiology, Purdue University, West Lafayette, IN. Gregory M Cresswell, PhD, Department of Comparative Pathobiology, Purdue University, West Lafayette, IN. Liang Cheng, MD, Pathology, Indiana University School of Medicine, Indianapolis, IN. Nadia Atallah Lamman, PhD, Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN. Travis Jerde, PhD, Pharmacology and Toxicology, Indiana School of Medicine, Indianapolis, IN. Bennett D Elzey, PhD, Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN. Timothy L Ratliff, PhD, Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN

https://drive.google.com/open?id=16W2nuGp7haQ9F_Wsy8cOWzpA1SXYj2M

**PS2-83**
Age-related Increased Incidence of Prostate Cancer was Revealed by a Spatially and Temporally Controlled Prostate-Specific Pten Knockout Mouse Model Generated through Adenovirus-Assisted In vivo Approach

Sen Liu, Tulane University
Bing Zhang, Jiwen Hu, S. Michal Jazwinski, Qiuyang Zhang

https://drive.google.com/open?id=10tXAefckikosA3YDyh4vb5RNYSUE5hTR7

**PS2-84**
Targeting GAPDH-related glycolysis in castration-resistant prostate cancers

Haixia Xu, MD, PhD, KUMC
Benyi Li, MD, PhD

https://drive.google.com/open?id=17YUdiEGioY0m8hnbbq6_XaCWFMpNfMNP
New Orleans Downtown Marriott at the Convention Center, New Orleans, Louisiana

Experience the unbridled energy and unique charm of The Big Easy when you stay at New Orleans Downtown Marriott at the Convention Center. Housed in a renovated 18th century cotton mill and bordering the Warehouse/Arts District, the CBD, the Garden District and the French Quarter, our four-star hotel successfully blends historic elegance with modern style. Intuitively designed rooms offer deluxe bedding, flat-screen TVs and views of the river or city. Featured amenities include a gym, an outdoor pool, 24-hour room service and Wolfe's, our popular restaurant featuring Creole and French favorites. Our hotel is a prime destination for business travelers, thanks to our flexible event venues and our proximity to the New Orleans Ernest Morial Convention Center, across the street. With so many New Orleans attractions and the Arts/Warehouse District at your fingertips, you'll never be short of things to do while you're here. Make plans for a remarkable stay at New Orleans Downtown Marriott at the Convention Center.

PARKING:
- Off-site parking, fee: 10 USD hourly, 30 USD daily
- Valet parking, fee: 39 USD daily
- Valet parking unavailable for oversized vehicles. Contact hotel valet for questions on alternate self parking options.

INTERNET:
- Guest rooms: Wireless, Wired
- High Speed: Check email + browse the Web for 10.95 USD/day
- Enhanced High Speed: Video chat, download large files + stream video for 14.95 USD/day
- Lobby and public areas: Complimentary Wireless
- Meeting rooms: Wireless, Wired

RESTAURANTS:
- Local restaurant dinner delivery
- Room service, 24-hour
- Sundry/Convenience store
- Breakfast Buffet, fee from 19.00 USD
- Continental breakfast, fee from 12.00 USD
- Full American breakfast, fee from 16.00 USD

Wolfe's (Creole) Get ready for a busy day in New Orleans with an energizing breakfast at our Warehouse District restaurant. Sample our contemporary Creole and French fare for lunch or dinner or enjoy evening cocktails at our elegant wine bar. Open for breakfast, lunch and dinner.

Dress code: Casual
Phone: +1 504-613-2888

Wolfe's Bar (American) Classic American and New Orleans food and beverages. Open for lunch and dinner.

Dress code: Casual
Phone: +1 504-613-2888

Starbucks* Stop by for your favorite coffee drink and treat as you head out for sightseeing or to events at the convention center near our downtown hotel. Grab a pick-me-up in the afternoon to recharge for an evening of fun in New Orleans. Open for breakfast and lunch.

Phone: +1 504-613-2888


FITNESS
- Fitness Center
- Swimming
- Outdoor Pool (3rd Floor)

GOLF
- Bayou Oaks at City Park (8.6 miles)
- South Course
- Audubon Park Golf Course (6 miles)
- Oak Harbor Country Club (30 miles)
- Chateau Golf & Country Club (14.8 miles)
- TPC of Louisiana (14.8 miles)
- English Turn Golf & Country Club (10.3 miles)

ADDITIONAL LOCAL AREA ATTRACTIONS
- Oak Harbor Country Club (8.5 miles)
- South Course
- Audubon Park Golf Course (6 miles)
- Oak Harbor Country Club (30 miles)
- Chateau Golf & Country Club (14.8 miles)
- TPC of Louisiana (14.8 miles)
- English Turn Golf & Country Club (10.3 miles)

FITNESS
- Fitness Center
- Swimming
- Outdoor Pool (3rd Floor)

ACTIVITIES
- Biking trail (1 mile)
- Boating (6 miles)
- Bowling (4.2 miles)
- Fly-fishing (1 mile)
- Horseback riding (12 miles)
- Jet-skiing (8 miles)
- Jogging/fitness trail (1 mile)

- Miniature golf (12.5 miles)
- Sailing (8 miles)
- Squash (0.4 miles)
- Outdoor Courts (3.2 miles)
- Volleyball (8 miles)
- Water-skiing (8 miles)

ADDITIONAL LOCAL AREA ATTRACTIONS
The Society for Basic Urologic Research (SBUR) was formed in 1986 and is the pre-eminent US-based urologic research society. Our members include molecular and developmental biologists, oncologists, immunologists, epidemiologists, andrologists, biochemists, bioinformaticians, and clinical urologic surgeon-scientists from academia, industry and government. SBUR scientists’ expertise includes the study of urologic cancers (prostate, bladder, kidney, testis, penis), the biology of benign diseases of the prostate, bladder and kidney, developmental biology, kidney and bladder function, autoimmune urologic diseases, infectious diseases, neuro-urologic diseases, male reproductive biology, infertility and erectile dysfunction.

SBUR was organized to:
- Provide a forum through the annual meeting for the presentation and discussion of basic, translational, and clinical scientific topics related to urology
- Promote advocacy and the interests of urologic disease investigators with national funding agencies, industry representatives and academic institutions with regards to urology related research
- Promote collaborations among member scientists and exchange of expertise between clinical and basic scientists
- Develop educational forums concerning scientific advancements related to the field of urology
- Serve as a resource for research information and expertise to clinical urologists through the American Urological Association and Urological societies worldwide.

SBUR is proud to offer our members outstanding scientific meetings in the Spring and Fall each year, and discounts to other meetings. Members are eligible for prestigious awards that include the Young Investigator Award, Eula and Donald S. Coffey Innovative Research Award, Trainee Travel Awards, Distinguished Service and Meritorious Achievement Award. We offer access to our network of experts for mentoring and career advice. Members also receive early access to job and fellowship opportunities.

Members are encouraged to contribute to sustain these important programs. If you wish to learn more or donate, please contact SBUR at (630) 463 -9015 or sbur@affinity-strategies.com. SBUR is granted tax-exempt status by the Internal Revenue Service as a Section 501(c)(3) charitable/educational organization. All contributions are tax deductible. Tax ID# 36-3607930.

Save The Date!

SBUR at AUA2020
May 16, 2020 in Washington, D.C.

SBUR 2020 Annual Meeting
November 12-15, 2020 in San Antonio, TX